2018-09-30 10Q Q3

0000926617-18-000072.txt : 20181108 0000926617-18-000072.hdr.sgml : 20181108 20181108162739 ACCESSION NUMBER: 0000926617-18-000072 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181108 DATE AS OF CHANGE: 20181108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERMILLION, INC. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 181170056 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 10-Q 1 vrml-20180930x10q.htm 10-Q 2018-09-30 10Q Q3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission file number: 001-34810

Vermillion, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware		33-0595156
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)
12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas		78738
(Address of Principal Executive Offices)		(Zip Code)

(512) 519-0400

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☐	Smaller reporting company ☑ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of October 31, 2018, the registrant had 75,382,684 shares of common stock, par value $0.001 per share, outstanding.

VERMILLION, INC.

FORM 10-Q

For the Quarter Ended September 30, 2018

Table of Contents


		Page
PART I	Financial Information	4
Item 1	Financial Statements	4
	Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 (unaudited)	4
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4	Controls and Procedures	26
PART II	Other Information	27
Item 1	Legal Proceedings	27
Item 1A	Risk Factors	27
Item 6	Exhibits	28
SIGNATURES		29

Vermillion, OVA1 and Overa are registered trademarks of Vermillion, Inc.

PART I - FINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

Vermillion, Inc.

Condensed Consolidated Balance Sheets

(Amounts in Thousands, Except Share and Par Value Amounts)

(Unaudited)


	September 30,		December 31,
	2018		2017
Assets
Current assets:
Cash and cash equivalents	$	11,760	$	5,539
Accounts receivable, net		656		205
Prepaid expenses and other current assets		242		459
Inventories		115		102
Total current assets		12,773		6,305
Property and equipment, net		701		1,181
Other assets		-		11
Total assets	$	13,474	$	7,497

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	495	$	745
Accrued liabilities		1,741		1,650
Short-term debt		188		185
Other current liabilities		-		29
Total current liabilities		2,424		2,609
Non-current liabilities:
Long-term debt		1,340		1,481
Total liabilities		3,764		4,090
Commitments and contingencies (Note 3)
Stockholders’ equity:
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized at
September 30, 2018 and December 31, 2017; none issued and outstanding at
September 30, 2018 and December 31, 2017		-		-
Common stock, par value $0.001 per share, 150,000,000 shares authorized at
September 30, 2018 and December 31, 2017; 75,382,684 and 60,036,017 shares
issued and outstanding at September 30, 2018 and December 31, 2017,
respectively		75		60
Additional paid-in capital		413,739		399,400
Accumulated deficit		(404,104)		(396,053)
Total stockholders’ equity		9,710		3,407
Total liabilities and stockholders’ equity	$	13,474	$	7,497

See accompanying notes to the unaudited condensed consolidated financial statements.

Vermillion, Inc.

Condensed Consolidated Statements of Operations

(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Revenue:
Product	$	739	$	657	$	1,979	$	2,195
Service		35		42		152		128
Total revenue		774		699		2,131		2,323
Cost of revenue:(1)
Product		477		495		1,538		1,345
Service		301		284		851		855
Total cost of revenue		778		779		2,389		2,200
Gross profit (loss)		(4)		(80)		(258)		123
Operating expenses:
Research and development(2)		129		192		425		685
Sales and marketing(3)		1,343		1,050		4,046		3,114
General and administrative(4)		1,167		1,177		3,780		3,825
Total operating expenses		2,639		2,419		8,251		7,624
Loss from operations		(2,643)		(2,499)		(8,509)		(7,501)
Interest income (expense), net		(6)		(10)		(25)		(32)
Other income (expense), net		(3)		-		(17)		(9)
Net loss	$	(2,652)	$	(2,509)	$	(8,551)	$	(7,542)
Deemed dividend on warrant repricing		-		(942)		-		(942)
Net loss attributable to common stockholders	$	(2,652)	$	(3,451)	$	(8,551)	$	(8,484)
Net loss per share attributable to common stockholders - basic and diluted	$	(0.04)	$	(0.06)	$	(0.13)	$	(0.15)
Weighted average common shares used to compute basic and diluted net loss per common share		75,306,074		57,455,786		68,288,216		55,909,788
Non-cash stock-based compensation expense included in cost of revenue and operating expenses:
(1) Cost of revenue	$	35	$	29	$	93	$	108
(2) Research and development		2		2		4		7
(3) Sales and marketing		14		38		85		115
(4) General and administrative		245		257		657		767

See accompanying notes to the unaudited condensed consolidated financial statements.

Vermillion, Inc.

Condensed Consolidated Statements of Cash Flows

(Amounts in Thousands)

(Unaudited)


	Nine Months Ended
	September 30,
	2018		2017
Cash flows from operating activities:
Net loss	$	(8,551)	$	(7,542)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		527		599
Stock-based compensation expense		839		997
Loss on sale and disposal of property and equipment		11		4
Changes in operating assets and liabilities:
Accounts receivable		49		54
Prepaid expenses and other assets		228		312
Inventories		(13)		(62)
Accounts payable, accrued liabilities and other liabilities		(159)		(401)
Deferred revenue		-		62
Net cash used in operating activities		(7,069)		(5,977)
Cash flows from investing activities:
Purchase of property and equipment		(58)		(56)
Net cash used in investing activities		(58)		(56)
Cash flows from financing activities:
Proceeds from private placement offering of common stock, net of issuance costs		-		5,127
Proceeds from public offering of preferred stock, net of issuance costs		4,496		-
Proceeds from public offering of common stock, net of issuance costs		8,990		-
Proceeds from exercise of common stock from exercise of warrants, net of issuance costs		-		3,577
Principal repayment of DECD loan		(138)		(136)
Repayment of capital lease obligations		(29)		(25)
Proceeds from issuance of common stock from exercise of stock options		29		-
Net cash provided by financing activities		13,348		8,543
Net increase in cash and cash equivalents		6,221		2,510
Cash and cash equivalents, beginning of period		5,539		5,242
Cash and cash equivalents, end of period	$	11,760	$	7,752
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$	33	$	36
Supplemental disclosure of non-cash investing and financing activities:
50,000 shares of convertible preferred stock converted to 5,000,000 shares of common stock, net of issuance costs	$	4,496	$	-
Deemed dividend on warrant repricing	$	-	$	942

See accompanying notes to the unaudited condensed consolidated financial statements.

Vermillion, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES

Organization

Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company,” “we” or “our”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”).

The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays.

Liquidity

The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $404,104,000 at September 30, 2018. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2018. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. However, management believes that the current working capital position will be sufficient to meet the Company’s working capital needs for at least the next 12 months.

As discussed in Note 4, on April 17, 2018, the Company completed two public offerings, pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses.

As discussed in Note 4, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,577,000 after deducting offering expenses.

As discussed in Note 4, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses.

As discussed in Note 3, in March 2016, the Company entered into an agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty.

Basis of Presentation

opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period.

The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2017 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 13, 2018 (the “2017 Annual Report”).

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.

Significant Accounting and Reporting Policies

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which it adopted on January 1, 2018 using the modified retrospective method.

In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services.

Product Revenue

Prior to January 1, 2018, the Company recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC 606, all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year.

The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the three and nine months ended September 30, 2018.

recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time.

The following tables show the impact of adoption to our consolidated statement of operations and balance sheet:



Nine Months Ended September 30, 2018
	Impact of changes in accounting policies
(in thousands, except per share amounts)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Product revenue	$	1,979	$	1,994	$	(15)
Operating loss	$	(8,509)	$	(8,494)	$	(15)
Net loss	$	(8,551)	$	(8,536)	$	(15)
Net loss per share, basic and diluted	$	(0.13)	$	(0.12)	$	-


September 30, 2018
	Impact of changes in accounting policies
(in thousands)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Assets:
Accounts receivable	$	656	$	171	$	485
Stockholders' equity:
Accumulated deficit	$	(404,104)	$	(404,589)	$	485

ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above tables.

Other Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Service Revenue

The Company’s service revenue is generated by performing IVD trial services for third-party customers. Application of the modified retrospective method did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes.

Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements.

Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting. This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards. This amendment is effective for annual periods after December 15, 2018. The Company is currently evaluating the impact of adoption of this standard.

In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). This guidance is intended to make leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 will be effective for interim and annual periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited and early adoption is permitted. The Company expects to adopt this standard beginning in 2019. Currently, our only significant leases are our two office leases.The Company is still evaluating the effect adoption will have on our financial statements. We expect to complete our evaluation during the fourth quarter.

In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.

2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED

In March 2015, the Company entered into a commercial agreement with Quest Diagnostics, Incorporated (“Quest Diagnostics”). Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2019 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers.

3. COMMITMENTS AND CONTINGENCIES

Development Loan

On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026. As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified

institutional lender. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”). Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date, or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan.

An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty.

Operating Leases

The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used by ASPiRA IVD is located in Trumbull, Connecticut. The Austin, Texas lease includes an aggregate annual base rent of $86,000 and annual estimated common area charges, taxes and insurance of $46,000 and expires on January 31, 2019.

In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000. The term of the lease is five years beginning after the initial date of occupancy in January 2016 and a rent abatement period of five months. The lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $95,000.

Building rent for the three months ended September 30, 2018 and 2017 totaled $66,000 for each period. Building rent for the nine months ended September 30, 2018 and 2017 totaled $199,000 and $189,000, respectively.

Non-cancelable Royalty Obligations

The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property. Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500. Royalty expense for the three months ended September 30, 2018 and 2017 totalled $30,000 for each period. Royalty expense for the nine months ended September 30, 2018 and 2017 totalled $78,000 and $94,000, respectively.

4. STOCKHOLDERS’ EQUITY

2018 Offerings

On April 13, 2018, the Company entered into two underwriting agreements (each, an “Underwriting Agreement”) with Piper Jaffray & Co., as the sole underwriter (the “Underwriter”), in connection with separate but concurrent public offerings of the Company’s securities.

Pursuant to the first Underwriting Agreement, the Company agreed to issue and sell an aggregate of 10,000,000 shares of Vermillion common stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $1.00 per share (the “Common Stock Offering”). Under this Underwriting Agreement, the Company granted the Underwriter an option to purchase up to an additional 1,500,000 shares of Vermillion common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The Underwriter did not exercise this option. The Common Stock Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $8,992,000.

Pursuant to the second Underwriting Agreement, the Company agreed to issue and sell an aggregate of 50,000 shares of Vermillion Series B Convertible Preferred Stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $100.00 per share (the “Series B Offering”). The Series B Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $4,496,000.

Upon obtaining Company stockholder approval at the annual meeting of Company stockholders on June 21, 2018, each of the 50,000 shares of Vermillion Series B Convertible Preferred Stock was automatically converted into shares of Vermillion common stock, at a conversion rate of 100 shares of Vermillion common stock per one share of Vermillion Series B Convertible Preferred Stock, including shares issuable pursuant to customary anti-dilution provisions.

2017 Warrant Repricing and Exercise

In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock.

On August 31, 2017, certain holders of these warrants exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock. The remaining 369,841 unexercised warrants expired by their original terms on December 23, 2017.

The Company issued 3,796,818 shares of Vermillion common stock and received $3,796,818 in aggregate gross proceeds (approximately $3,577,000 net of transaction costs). The incremental non-cash fair value of approximately $942,000 from the modification of the warrants was calculated using the Black-Scholes model and recorded as a deemed dividend to the warrant holders within stockholders’ equity.

2017 Private Placement

On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of Vermillion common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,127,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period.

The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stock is approximately $4,296,000.

2010 Stock Incentive Plan

The Company’s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 12,122,983 shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan.

Stock-Based Compensation

During the three months ended September 30, 2018, the Company awarded Vermillion’s non-employee directors an aggregate of 27,871 shares of restricted stock under the 2010 Plan having a fair value of approximately $35,000. The vesting of these shares of restricted stock is as follows: 32% on September 1, 2018, and 68% on December 1, 2018. The Company also awarded a certain consultant 16,816 shares of restricted stock under the 2010 Plan having a fair value of approximately $13,000.

During the nine months ended September 30, 2018, the Company awarded Vermillion’s non-employee directors an aggregate of 398,400 shares of restricted stock under the 2010 Plan having a fair value of approximately $442,000. The vesting of these shares of restricted stock is as follows: 50% on June 1, 2018, 25% on September 1, 2018 and 25% on December 1, 2018. 35,000 of those shares of restricted stock were forfeited upon the departure of a board member in June. The Company also awarded certain consultants 23,350 shares of restricted stock under the 2010 Plan having a fair value of approximately $23,000.

During the nine months ended September 30, 2018, the Company granted certain officers and employees options to purchase an aggregate of 934,000 shares of Vermillion common stock with an exercise price of $1.11 per share and 125,000 shares of Vermillion common stock with an exercise price of $0.90 per share. These stock options vest 25% on each of the four anniversaries of the vesting commencement date for each such stock option.

The allocation of employee stock-based compensation expense by functional area for the three and nine months ended September 30, 2018 and 2017 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2018		2017		2018		2017
Cost of revenue	$	22	$	21	$	69	$	61
Research and development		2		-		4		5
Sales and marketing		14		38		95		108
General and administrative		233		216		727		630
Total	$	271	$	275	$	895	$	804

5. LOSS PER SHARE

The Company calculates basic loss per share using the weighted average number of shares of Vermillion common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Vermillion common stock outstanding and excludes the effects of 7,414,053 and 7,971,860 potential shares of Vermillion common stock as of September 30, 2018 and 2017, respectively, that are anti-dilutive. Potential shares of Vermillion common stock include incremental shares of Vermillion common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.

6. RELATED PARTY TRANSACTIONS

On December 18, 2017, the Company entered into a consulting agreement for a term of up to five months with the Company’s former Senior Vice President, Finance and Chief Accounting Officer. Pursuant to the terms of the consulting agreement through May 15, 2018, the consultant provided accounting and finance services related to the transition of financial leadership. The Company agreed to pay $150 per hour for such consulting services. The consultant also remained eligible for payout under the Company’s 2017 Corporate Incentive Plan after he satisfactorily met certain performance obligations as outlined in the consulting agreement. During the nine months ended September 30, 2018, the consultant was paid an aggregate of $53,925 for services provided pursuant to the consulting agreement.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995.

These statements involve a number of risks and uncertainties. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements speak only as of the date on which this Quarterly Report on Form 10-Q is filed with the Securities and Exchange Commission (the “SEC”), and, except as required by law, Vermillion, Inc. (“Vermillion” and, together with its subsidiaries, the “Company,” “we,” “our,” or “us”) does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after such date.

Examples of forward-looking statements regarding our business include the following:

projections or expectations regarding our future test volumes, revenue, cost of revenue, operating expenses, cash flow, results of operations and financial condition;

our plan to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological disorders;

our planned business strategy and the anticipated timing of the implementation thereof;

plans with respect to our market expansion and growth, including plans to market OVA1 and Overa outside the United States;

plans to develop new algorithms and molecular diagnostic tests;

plans to develop a product or tool combining an OVA1 with results of a symptom index;

plans to establish our own payer coverage for Overa and expand coverage for OVA1;

intentions to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and other issues in the fields of oncology and women’s health;

plans to leverage infrastructure and enhance our pipeline of future technologies by fostering relationships with in vitro diagnostic (“IVD”) companies;

plans with respect to ASPiRA IVD, Inc. (“ASPiRA IVD”);

expected service revenue

our planned focus on the execution of five core strategic business drivers in ovarian cancer diagnostics and specialized laboratory services to address unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business;

anticipated efficacy of our products, product development activities and product innovations;

expected competition in the markets in which we compete;

plans with respect to ASPiRA LABS, Inc. (“ASPiRA LABS”);

expectations regarding future services provided by Quest Diagnostics Incorporated (“Quest Diagnostics”);

plans to expand our ovarian cancer franchise beyond OVA1, including with respect to Overa, OVA1/Overa Reflex, and DxA1 and DxA2;

plans regarding the commercialization of Overa;

plans to decentralize OVA1 testing to physician offices and healthcare systems;

plans to develop informatics products and develop and perform laboratory developed tests (“LDTs”);

plans with respect to the Company’s pelvic mass registry, including anticipated sources of funding;

anticipated effects on reimbursement for OVA1 from changes to Novitas Solutions’ administrative requirements;

expectations regarding the Company’s approach of monitoring and combining multiple protein biomarkers to create diagnostic tests to aid physicians considering treatment options for patients with complex diseases, and the Company’s future development of new In Vitro Diagnostic Multivariate Index Assays (IVDMIA);

expectations regarding existing and future collaborations and partnerships, including OVA1 and Overa distribution agreements;

plans regarding future publications;

our continued ability to comply with applicable governmental regulations, expectations regarding pending regulatory submissions and plans to seek regulatory approvals for our tests outside the United States;

our ability to obtain and maintain the regulatory approvals required to market Overa in other countries;

our continued ability to expand and protect our intellectual property portfolio;

anticipated liquidity and capital requirements;

anticipated future losses and our ability to continue as a going concern;

expectations regarding the second disbursement from our financing arrangement, as amended, with the State of Connecticut Department of Economic and Community Development (the “DECD”);

expected expenditures, including the expected increase in expenses related to sales and marketing of OVA1 and Overa in 2018;

our ability to use our net operating loss carryforwards;

anticipated future tax liability under U.S. federal and state income tax legislation;

expected market adoption of our diagnostic tests, including OVA1 and Overa;

expectations regarding our ability to launch new products we develop, license, co-market or acquire;

expectations regarding raising capital and the amount of financing anticipated to be required to fund our planned operations; and

expectations regarding reimbursement for our products, and our ability to obtain such reimbursement, from third-party payers such as private insurance companies and government insurance plans.

Forward-looking statements are subject to significant risks and uncertainties, including those discussed in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017 (our “2017 Annual Report”), that could cause actual results to differ materially from those projected in such forward-looking statements due to various factors, including our ability to increase the volume of OVA1 or Overa sales; our ability to market our test through sales channels other than Quest Diagnostics including ASPiRA LABS; failures by third-party payers to reimburse OVA1 or Overa or changes or variances in reimbursement rates; our ability to secure additional capital on acceptable terms to execute our business plan; our ability to commercialize OVA1 or Overa both within and outside the United States; in the event that we succeed in commercializing OVA1 or Overa outside the United States, the political, economic and other conditions affecting other countries (including foreign exchange rates); our ability to continue developing certain existing technologies; our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our future diagnostic products; our or our suppliers’ ability to comply with Food and Drug Administration (“FDA”) requirements for production, marketing

and post-market monitoring of our products; additional costs that may be required to make further improvements to our manufacturing operations; our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; our ability to continue to develop, protect and promote our proprietary technologies; our ability to use intellectual property directed to diagnose biomarkers; our ability to successfully defend our proprietary technology against third parties; future litigation against us, including infringement of intellectual property and product liability exposure; our ability to retain key employees; business interruptions; legislative actions resulting in higher compliance costs; changes in healthcare policy; our ability to comply with environmental laws; our ability to generate sufficient demand for ASPiRA LABS’ services to cover its operating costs; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of ASPiRA LABS; our ability to comply with FDA regulations that relate to our products and to obtain any FDA clearance or approval required to develop and perform LDTs; ASPiRA IVD’s lack of operating history; ASPiRA IVD’s ability to generate and maintain business; fluctuations over time with respect to ASPiRA IVD’s operating results; ASPiRA IVD’s ability to enter into profitable contracts; ASPiRA IVD’s ability to maintain effective information systems without significant interruption; ASPiRA IVD’s ability to perform its services in compliance with contractual requirements, regulatory standards and ethical considerations; our ability to integrate and achieve anticipated results from any acquisitions or strategic alliances; and our ability to comply with continued listing requirements of The Nasdaq Capital Market.

Overview

Our vision is to drive the advancement of women’s health by providing innovative methods to detect, monitor and manage the treatment of both benign and malignant gynecologic disease, with our primary focus being diseases of the female pelvic cavity.

We have expanded our corporate strategy with the goal of transforming Vermillion from a technology license company to a diagnostic service and bio-analytic solutions provider. Our plan is to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological disorders. Our strategy is being deployed in three phases. The three phases are a rebuild phase, which was completed in the third quarter of 2015, a transformation phase, which is now virtually complete except for continuing expansion of payer coverage, and a market expansion and growth phase, which we began in 2017.

During the first phase, we expanded our leadership team by hiring several new senior leaders including a chief executive officer. In addition, we expanded our commercial strategy, reestablished medical and advisory support, rebuilt our patient advocacy strategy and established a billing system and a payer strategy outside of our relationship with Quest Diagnostics. During the second phase, we completed the process of obtaining licensure of ASPiRA LABS in all of the states that require licenses, and are in the process of establishing our own payer coverage for OVA1, Multivariate Index Assay (MIA), and our second-generation OVA1 test, trademarked Overa, Multivariate Index Assay, 2nd Generation (MIA2G). Overa has been launched on a targeted basis. In October, we launched OVA1+, which is designed to improve accuracy and reduce false positives by nearly 40% by leveraging the strengths of OVA1’s sensitivity and Overa’s specificity. In the third phase, we plan to fully commercialize OVA1 and Overa by utilizing the full national licensure of ASPiRA LABS, select laboratories for distribution, decentralized OVA1 testing to physician offices and healthcare systems, managed care coverage in select markets, our sales force and existing customer base. Unlike OVA1, Overa uses a global testing platform, which will allow Overa to be deployed internationally. We initiated the targeted launch of Overa in October 2016 with two key accounts converting from OVA1 to Overa. In October 2015, we announced registration of the CE mark for and clearance to market Overa in the European Union. We also plan to develop an LDT product series, which we refer to internally as Diagnostic Algorithms #1 (“DxA1”) and Diagnostic Algorithms #2 (“DxA2”). We anticipate that DxA1 and DxA2 will include not only biomarkers, but also clinical risk factors, other diagnostics and patient history data in order to boost predictive value. During the third quarter, we reorganized and reinvested in a stronger sales and marketing team in order to better position our new commercial offerings.

We are dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. Our tests are intended to detect, characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy. A distinctive feature of our approach is to combine multiple biomarkers, other modalities and diagnostics, clinical risk factors and patient data into a single, reportable index score that has higher diagnostic

accuracy than its constituents. We concentrate on our development of novel diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. We also intend to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and research institutions.

Our initial product, OVA1, is an FDA-cleared blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery. We have launched on a targeted basis a second-generation biomarker panel known as Overa, which is intended to maintain our product’s high sensitivity while improving specificity. We received FDA clearance for Overa in March 2016. Overa uses the Roche cobas 4000, 6000 and 8000 platforms.

In June 2014, Vermillion launched ASPiRA LABS, a Clinical Laboratory Improvements Amendments of 1988 (“CLIA”) certified national laboratory based in Austin, Texas, which specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. ASPiRA LABS provides expert diagnostic services using a state-of-the-art biomarker-based diagnostic algorithm to aid in clinical decision making and advance personalized treatment plans. The lab currently processes our OVA1 and Overa tests, and we plan to develop and perform LDTs at ASPiRA LABS in the future. ASPiRA LABS holds a CLIA Certificate of Registration and a state laboratory license in California, Florida, Maryland, New York, Pennsylvania and Rhode Island. The Centers for Medicare & Medicaid Services issued a provider number to ASPiRA LABS in March 2015.

In 2016, we created a new service within the ASPiRA channel strategy, “an ASPiRA IVD Services Program”. In April 2016, we formed ASPiRA IVD to offer IVD trial services to third-party customers. ASPiRA IVD is a specialized laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and an FDA-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission. ASPiRA IVD received a CLIA laboratory license in June 2016 and commenced operations in the second quarter of 2016.

Strategy:

We are focused on the execution of five core strategic business drivers in ovarian cancer diagnostics and specialized laboratory services to build long-term value for our investors:

Maximizing the existing OVA1 opportunity in the United States by taking the lead in payer coverage and commercialization of OVA1. This strategy included the launch of a CLIA certified clinical laboratory, ASPiRA LABS, in June 2014;

Expanding the distribution platform beyond the U.S. by launching Overa, a next generation biomarker panel, while building the clinical utility and health economics foundation of both OVA1 and Overa, which we believe may allow for better domestic market penetration and international expansion (FDA clearance for Overa was received in March 2016);

Leveraging our existing database and specimen bank while building the largest specimen and data repository of gynecologic pelvic mass patients worldwide;

Expanding our product offerings to additional pelvic disease conditions such as endometriosis and polycystic ovarian syndrome by adding additional gynecologic bio-analytic solutions involving biomarkers, other modalities (e.g., imaging), clinical risk factors and patient data to aid diagnosis and risk stratification of women presenting with a pelvic mass disease; and

Expanding our customer offerings with the launch of our ASPiRA IVD laboratory services.

We believe that these business drivers will contribute significantly to addressing unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business.

OVA1 addresses a clear clinical need, namely the pre-surgical identification of women who are at risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to gynecologic oncologists for their initial surgery. Prior to the clearance of OVA1, no blood test had been cleared by the FDA for physicians to use in the pre-surgical management of ovarian adnexal masses. OVA1 is a qualitative serum test that utilizes five well-established biomarkers and proprietary software cleared as part of the OVA1 510(k) to determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of OVA1 carries the risk of unnecessary testing, surgery and delayed diagnosis. OVA1 was developed through large pre-clinical studies in collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated.

In the United States, revenue for diagnostic tests comes from several sources, including third-party payers such as insurance companies, government healthcare programs, such as Medicare and Medicaid, client bill accounts and patients. Novitas Solutions, the Medicare contractor, covers and reimburses for OVA1 tests performed in certain states, including Texas. Because OVA1 tests are exclusively performed at ASPiRA LABS in Texas this local coverage determination from Novitas Solutions essentially provides national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. ASPiRA LABS also bills third-party commercial and other government payers as well as client bill accounts and patients for OVA1.

In October 2016, we launched our pelvic mass specimen and data repository and began the collection of Institutional Review Board patient consents for collection and cataloguing of serum samples for future research purposes.

In November 2016, The American College of Obstetricians and Gynecologists ("ACOG”) issued Practice Bulletin Number 174 which included OVA1 as a “Multivariate Index Assay”. This bulletin outlines ACOG's “new” clinical management guidelines for adnexal mass management.

These new clinical management guidelines replace the July 2007 version, Practice Bulletin 83. Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. Practice Bulletins are evidence-based documents, and recommendations are based on the evidence. This is also the only clinical management tool used for adnexal masses. Guidelines do not exist for adnexal masses, only Practice Bulletins. Guidelines do exist, however, for ovarian cancer management.

The Practice Bulletin recommends that obstetricians and gynecologists evaluating women with adnexal masses who do not meet Level A criteria of a low risk transvaginal ultrasound should proceed with Level B clinical guidelines. Level B guidelines state that the physician may use risk assessment tools such as existing CA125 technology or OVA1 (“Multivariate Index Assay”) as listed in the bulletin. Based on this, OVA1 has now achieved parity with CA125 as a Level B recommendation for the management of adnexal masses.

In December 2016, we received an FDA Clarification Letter regarding OVA1 and Overa. This letter was in reference to the September 7, 2016 FDA Safety Communication advising women and their physicians against the use of ovarian cancer screening tests for asymptomatic women.

In order to avoid any confusion, as well as to document the FDA position on OVA1 and Overa, Jeffrey Shuren, M.D., J.D., Director for the Center for Devices and Radiological Health at the FDA, sent a letter to Vermillion, dated December 21, 2016. In the letter, Dr. Shuren stated:

We agree that this safety communication does not apply to Vermillion’s FDA-cleared tests, OVA1 (MIA) and Overa (MIA2G), which are not screening tests for ovarian cancer.

FDA cleared OVA1 (MIA) and Overa (MIA2G) as aids to further assess the likelihood that malignancy is present when the physician’s independent clinical and radiological evaluation does not indicate malignancy. The intended uses of the two assays are the same—to help physicians more reliably identify which patients would benefit from consultation with or referral to a

gynecologic oncologist. OVA1 (MIA) and Overa (MIA2G) are indicated for women who present with an adnexal mass.

In March 2015, we entered into a new commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 10, 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2019 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers.

In 2016, we continued to make progress with increased payer positive medical polices and in network agreements for a total of over 80 million covered lives.

In the first half of 2017, ASPiRA IVD services landed two top pharmaceutical trial service agreements including one enrollment study.

In July 2017, ASPiRA LABS expanded its patient advocacy program nationally to assist patients with proactive benefit checks, with over 90% resulting in OVA1 utilization.

In September 2017, the preliminary Protecting Access to Medicare Act of 2014 (“PAMA”) price for OVA1 and Overa was published by the Center for Medicare and Medicaid Service. The preliminary OVA1 rate is based on the median of private payer payments we submitted as part of the market-based payment reforms mandated through PAMA. The Overa price was benchmarked to the only proteomic test currently on the fee schedule, which uses biomarkers and an algorithm to produce a prognostic score. Under the new fee schedule effective January 1, 2018, the price for OVA1 (MIA) (code 81503) is $897 and the price for Overa is $950.

In 2018, we have continued to make progress with increased payer positive medical polices and in network agreements. As of September 30, 2018, we had 131 million covered lives and 112 million lives under contract agreement.

In October 2018, ASPiRA LABS launched OVA1®+, a new clinical pathway which combines the strengths of OVA1® and Overa®. The new offering improves accuracy and reduces false positives by nearly 40%.

As of the fourth quarter of 2018, we have launched our new platform and cloud service for decentralizing OVA1 testing. The platform and web service will allow other facilities to perform OVA1 and calculate OVA1 scores locally, enabling increased reach and access in the markets we serve.

Recent Developments

On April 17, 2018, the Company completed two underwritten public offerings, pursuant to which certain investors purchased 10,000,000 shares of Vermillion common stock, par value $0.001 per share, for $1.00 per share (the “Common Stock Offering”) and 50,000 shares of Vermillion Series B convertible preferred stock, par value $0.001 per share, for $100.00 per share (the “Series B Offering” and, together with the Common Stock Offering, the “Offerings”) for net proceeds of approximately $13,500,000 after deducting offering expenses.

On July 24, 2018, the Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued

inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Company has the opportunity to regain compliance or produce a plan to regain compliance. However, there can be no assurance that the Company will regain compliance.

Effective August 17, 2018, the Company appointed Nancy G. Cocozza to its board of directors.

Critical Accounting Policies and Estimates

Prior to January 1, 2018, we recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. Our product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test result to the prescribing physician. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount to accrue for a delivered test result, we consider factors such as historical payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and us, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management. We also reviewed our patient account population and determined an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. When evaluated for collectability, this results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis.

Under the modified retrospective implementation method, we recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all OVA1 and Overa tests performed prior to January 1, 2018 as of revenue had been recognized under ASC 606. The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit.

Results of Operations - Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

The selected summary financial and operating data of the Company for the three months ended September 30, 2018 and 2017 were as follows:


	Three Months Ended September 30,				Increase (Decrease)
(dollars in thousands)	2018		2017		Amount		%
Revenue:
Product	$	739	$	657	$	82	12
Service		35		42		(7)	(17)
Total revenue		774		699		75	11
Cost of revenue:
Product		477		495		(18)	(4)
Service		301		284		17	6
Total cost of revenue		778		779		(1)	(0)
Gross profit (loss)		(4)		(80)		76	(95)
Operating expenses:
Research and development		129		192		(63)	(33)
Sales and marketing		1,343		1,050		293	28
General and administrative		1,167		1,177		(10)	(1)
Total operating expenses		2,639		2,419		220	9
Loss from operations		(2,643)		(2,499)		(144)	6
Interest income (expense), net		(6)		(10)		4	(40)
Other income (expense), net		(3)		-		(3)	-
Net loss		(2,652)		(2,509)		(143)	6
Deemed dividend on warrant repricing				(942)		942
Net loss attributable to common stockholders	$	(2,652)	$	(3,451)	$	799	6

Product Revenue. Product revenue was $739,000 for the three months ended September 30, 2018 compared to $657,000 for the same period in 2017. Effective January 1, 2018, revenue for ASPiRA LABS is being recognized when the OVA1 test is being performed based on estimates of what we expect to ultimately realize. The 12% product revenue increase is due to a slight increase in our tests performed, as well as an increase in price per test.

The number of OVA1 tests performed increased 1% to approximately 1,981 OVA1 tests during the three months ended September 30, 2018 compared to approximately 1,954 OVA1 tests for the same period in 2017. We expect the test volume to improve over the remainder of the year as we increase our sales and marketing investments.

Service Revenue. Service revenue was $35,000 for the three months ended September 30, 2018 compared to $42,000 for the same period in 2017. Service revenue varies from quarter to quarter based on the stages of ongoing customer projects. Revenue for ASPiRA IVD is being recognized once certain revenue recognition criteria have been met (see Note 1 to the financial statements included in Part I, Item I of this Form 10-Q). Due to the existing pipeline, we expect service revenue to increase slightly in the fourth quarter of 2018.

Cost of Revenue - Product. Cost of product revenue was $477,000 for the three months ended September 30, 2018 compared to $495,000 for the same period in 2017, representing a decrease of 4% due primarily to decreases in depreciation and lab supply costs, offset by postage costs due to new kits, as well as Quest project management fees incurred in 2018. We expect the cost of product revenue to remain consistent in the fourth quarter of 2018 compared to the third quarter of 2018.

Cost of Revenue - Service. Cost of service revenue was $301,000 for the three months ended September 30, 2018 compared to $284,000 for the same period in 2017. The 6% increase related primarily to lab supplies purchased in connection with larger projects in the third quarter of 2018. We expect the cost of service revenue to fluctuate consistent with service revenue to some extent; however, due to the fixed nature of the costs, we expect the fourth quarter costs to be largely consistent with those of the third quarter.

Research and Development Expenses. Research and development expenses represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory work, infrastructure expenses, contract services and other outside costs. Research and development expenses for the three months ended September 30, 2018 decreased $63,000, or 33%, compared to the same period in 2017. This decrease was primarily due to a reduction in consulting expenses. We expect research and development expenses to increase slightly from the third to the fourth quarter of 2018 due to the completion of ongoing studies and publications.

Sales and Marketing Expenses. Our sales and marketing expenses consist primarily of personnel-related expenses, education and promotional expenses, and infrastructure expenses. These expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1 and Overa. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation, and dissemination of scientific and health economic publications. Sales and marketing expenses for the three months ended September 30, 2018 increased $293,000, or 28%, compared to the same period in 2017. This increase was primarily due to increased headcount and personnel-related expenses and increased consulting costs in the third quarter of 2018 compared to 2017. We expect sales and marketing expenses to increase modestly over the remainder of 2018 as we focus efforts on the commercialization of OVA1 and Overa.

General and Administrative Expenses. General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses and other infrastructure expenses. General and administrative expenses for the three months ended September 30, 2018 decreased by $10,000, or 1%, compared to the same period in 2017. We expect general and administrative expenses to remain consistent with the third quarter in the fourth quarter of 2018.

Results of Operations - Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

The selected summary financial and operating data of the Company for the nine months ended September 30, 2018 and 2017 were as follows:


	Nine Months Ended September 30,				Increase (Decrease)
(dollars in thousands)	2018		2017		Amount		%
Revenue:
Product	$	1,979	$	2,195	$	(216)	(10)
Service		152		128		24	19
Total revenue		2,131		2,323		(192)	(8)
Cost of revenue:
Product		1,538		1,345		193	14
Service		851		855		(4)	(0)
Total cost of revenue		2,389		2,200		189	9
Gross profit (loss)		(258)		123		(381)	(310)
Operating expenses:
Research and development		425		685		(260)	(38)
Sales and marketing		4,046		3,114		932	30
General and administrative		3,780		3,825		(45)	(1)
Total operating expenses		8,251		7,624		627	8
Loss from operations		(8,509)		(7,501)		(1,008)	13
Interest income (expense), net		(25)		(32)		7	(22)
Other income (expense), net		(17)		(9)		(8)	89
Net loss		(8,551)		(7,542)		(1,009)	13
Deemed dividend on warrant repricing				(942)		942
Net loss attributable to common stockholders	$	(8,551)	$	(8,484)	$	(67)	13

Product Revenue. Product revenue was $1,979,000 for the nine months ended September 30, 2018 compared to $2,195,000 for the same period in 2017. Effective January 1, 2018, revenue for ASPiRA LABS is being recognized when the OVA1 test is being performed based on estimates of what we expect to ultimately realize. The 10% product revenue decrease is due to a decrease in our tests performed, especially those for client bill customers.

The number of OVA1 tests performed decreased 15% to approximately 5,683 OVA1 tests during the nine months ended September 30, 2018 compared to approximately 6,665 OVA1 tests for the same period in 2017. The volume decrease was primarily due to the previously announced loss of a client bill customer in July 2017, which was concentrated in uncovered territories (territories not covered by an ASPiRA sales representative).

Service Revenue. Service revenue was $152,000 for the nine months ended September 30, 2018 compared to $128,000 for the same period in 2017. Service revenue varies based on the stages of ongoing customer projects. Revenue for ASPiRA IVD is being recognized once certain revenue recognition criteria have been met (see Note 1 to the financial statements included in Part I, Item I of this Form 10-Q).

Cost of Revenue - Product. Cost of product revenue was $1,538,000 for the nine months ended September 30, 2018 compared to $1,345,000 for the same period in 2017, representing an increase of 14% due primarily to some equipment maintenance costs, increased postage costs as well as Quest project management fees incurred in 2018.

Cost of Revenue - Service. Cost of service revenue was $851,000 for the nine months ended September 30, 2018, which was nearly flat compared to $855,000 in costs for the same period in 2017.

Research and Development Expenses. Research and development expenses represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory work, infrastructure expenses, contract services and other outside costs. Research and development expenses for the nine months ended September 30, 2018 decreased $260,000, or 38%, compared to the same period in 2017. This decrease was primarily due to a reduction in consulting expenses.

Sales and Marketing Expenses. Our sales and marketing expenses consist primarily of personnel-related expenses, education and promotional expenses, and infrastructure expenses. These expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1 and Overa. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation, and dissemination of scientific and health economic publications. Sales and marketing expenses for the nine months ended September 30, 2018 increased $932,000, or 30%, compared to the same period in 2017. This increase was primarily due to increased headcount and personnel-related expenses, one-time costs for Chief Operating Officer severance and increased consulting costs in 2018 compared to 2017.

General and Administrative Expenses. General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses and other infrastructure expenses. General and administrative expenses for the nine months ended September 30, 2018 decreased by $45,000, or 1%, compared to the same period in 2017. The decrease was primarily due to the remeasurement of consultant stock options in 2018 and reduced headcount, partially offset by increased consulting fees in 2018.

Liquidity and Capital Resources

We plan to continue to expend resources selling and marketing OVA1 and Overa, operating our IVD trial services business and developing additional diagnostic tests and service capabilities.

We have incurred significant net losses and negative cash flows from operations since inception. At September 30, 2018, we had an accumulated deficit of $404,104,000 and stockholders’ equity of $9,710,000. As of September 30, 2018, we had $11,760,000 of cash and cash equivalents and $2,424,000 of current liabilities. Working capital was $10,349,000 and $3,696,000 at September 30, 2018 and December 31, 2017, respectively.

On April 17, 2018, the Company completed the Offerings pursuant to which certain investors purchased shares of Vermillion common stock and shares of Vermillion Series B Convertible Preferred Stock for net proceeds of approximately $13,500,000 after deducting offering expenses.

On August 31, 2017, certain holders exercised warrants to purchase 3,796,818 shares of Vermillion common stock (which warrants were issued in conjunction with a December 2014 private placement of Vermillion common stock) in consideration for the Company agreeing to reduce the exercise price from $2.00 to $1.00 per share of Vermillion common stock. As a result, the Company issued 3,796,818 shares of Vermillion common stock and received $3,797,000 in aggregate gross proceeds (approximately $3,577,000 net of transaction costs).

On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses.

On March 22, 2016, we entered into the Loan Agreement pursuant to which we may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to our Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026. As security for the loan, we have granted the DECD a blanket security interest in our personal and intellectual property. The DECD’s security interest in our intellectual property may be subordinated to a qualified institutional lender. Under the terms of the agreement, as amended, we may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if we achieve certain job creation and

retention milestones measured by March 1, 2021 (the “Measurement Date”). Conversely, if we are either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date or do not maintain our Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty.

We expect to incur a net loss and negative cash flows from operations in the remainder of 2018. Our management believes that successful achievement of our business objectives may require additional financing.

The Company expects to raise capital, if necessary, through a variety of sources, which may include the exercise of common stock warrants, equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the Company’s business, results of operations and financial condition.

Net cash used in operating activities was $7,069,000 for the nine months ended September 30, 2018, resulting primarily from the net loss reported of $8,551,000, partially offset by depreciation and amortization of $527,000, stock compensation expense of $839,000, and changes in prepaid expenses of $228,000.

Net cash used in operating activities was $5,977,000 for the nine months ended September 30, 2017, resulting primarily from the net loss reported of $7,542,000 and changes in accounts payable, accrued and other liabilities of $401,000 partially offset by stock compensation expense of $997,000, depreciation and amortization of $599,000 and prepaid expenses of $312,000.

Net cash used in investing activities was $58,000 and $56,000 for the nine months ended September 30, 2018 and 2017, respectively, which consisted of property and equipment purchases.

Net cash provided by financing activities was $13,348,000 for the nine months ended September 30, 2018, resulting primarily from the proceeds from the sale of Vermillion preferred stock of $4,496,000 and of Vermillion common stock of $8,990,000 in our April 2018 public offering.

Net cash provided by financing activities was $8,543,000 for the nine months ended September 30, 2017, which consisted primarily of proceeds from the sale of Vermillion common stock in our February 2017 private placement, net of issuance costs, as well as proceeds from the exercise of common stock warrants, net of issuance costs.

Our future liquidity and capital requirements will depend upon many factors, including, among others:

resources devoted to sales, marketing and distribution capabilities;

the rate of OVA1 and Overa product adoption by physicians and patients;

the insurance payer community’s acceptance of and reimbursement for OVA1 and Overa;

the successful targeted launch of Overa;

resources devoted to our IVD trials laboratory and services;

the revenue generated by our IVD trial services business;

our plans to acquire or invest in other products, technologies and businesses; and

the market price of our common stock.

We have significant net operating loss (“NOL”) carryforwards as of September 30, 2018 for which a full valuation allowance has been provided due to our history of operating losses. Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions may restrict our ability to use our NOL credit carryforwards due to ownership change limitations occurring in the past or that could occur in the future. These ownership changes may also limit the amount of NOL credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.

New tax legislation, commonly referred to as the Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, Accounting for Income Taxes, requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since our federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect our financial statements. Significant provisions that are not yet effective but may impact income taxes in future years include: the repeal of the corporate Alternative Minimum Tax, the limitation on the current deductibility of net interest expense in excess of 30% of adjusted taxable income for levered balance sheets, a limitation on utilization of net operating losses generated after tax year 2017 to 80% of taxable income, the unlimited carryforward of net operating losses generated after tax year 2017, temporary 100% expensing of certain business assets, additional limitations on certain general and administrative expenses, and changes in determining the excessive compensation limitation. Currently, we do not anticipate paying cash federal income taxes in the near term due to any of the legislative changes, primarily due to the availability of our net operating loss carryforwards. Future interpretations relating to the recently enacted U.S. federal income tax legislation which vary from our current interpretation and possible changes to state tax laws in response to the recently enacted federal legislation may have a significant effect on this projection.

Off-Balance Sheet Arrangements

As of September 30, 2018, we had no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on our condensed consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.


ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Per Item 305(e) of Regulation S-K, the information called for by this Item 3 is not required.


ITEM 4.	CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures.

Our senior management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management, including our Chief Executive Officer and Chief Financial Officer, performed an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2018. Based on this evaluation, our Chief Executive Officer and

Chief Financial Officer have concluded that as of September 30, 2018, our disclosure controls and procedures were effective.

Changes in internal controls over financial reporting.

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION


ITEM 1.	LEGAL PROCEEDINGS

In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially and adversely affect our results of operations, cash flows and financial position. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management resources and other factors. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters, as of September 30, 2018, that, in the opinion of management, will have a material adverse effect on our financial position, results of operations or cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors from those disclosed under “Risk Factors” in Part I, Item 1A of our 2017 Annual Report, as supplemented by the risk factor disclosed under “Risk Factors” in Part II, Item 1A of our quarterly report on Form 10-Q for the quarter ended June 30, 2018, filed with the SEC on August 9, 2018. The risks and uncertainties described in our 2017 Annual Report, as supplemented, are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations.

ITEM 6. EXHIBITS The following exhibits are filed or incorporated by reference with this report as indicated below:

Exhibit

Incorporated by Reference

Filed

Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Herewith

3.1

Fourth Amended and Restated Certificate of Incorporation of Vermillion, Inc. dated January 22, 2010

8-K

000-31617

3.1

January 25, 2010

3.2

Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation, effective June 19, 2014

10-Q

001-34810

3.2

August 14, 2014

3.3

Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock

8-K

001-34810

4.1

April 17, 2018

3.4

Fifth Amended and Restated Bylaws of Vermillion, Inc., effective June 19, 2014

10-Q

001-34810

3.3

August 14, 2014

31.1

Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

√

31.2

Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

√

32.1

Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1)

101

Interactive Data Files

√


(1)	Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Vermillion, Inc.
Date: November 8, 2018	/s/ Valerie B. Palmieri
	Valerie B. Palmieri President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)
Date: November 8, 2018	/s/ Robert Beechey
	Robert Beechey Chief Financial Officer (Duly Authorized Officer, Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 vrml-20180930xex31_1.htm EX-31.1 Exhibit 31.1

Exhibit 31.1

Certification of the Chief Executive Officer Pursuant to Section 302 of

The Sarbanes-Oxley Act Of 2002

I, Valerie B. Palmieri, certify that:

I have reviewed this quarterly report on Form 10-Q of Vermillion, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2018

/s/ Valerie B. Palmieri

Valerie B. Palmieri

President and Chief Executive Officer

(Duly Authorized Officer and Principal Executive Officer)

EX-31.2 3 vrml-20180930xex31_2.htm EX-31.2 Exhibit 31.2

Exhibit 31.2

Certification of the Chief Accounting Officer Pursuant to Section 302 of

The Sarbanes-Oxley Act Of 2002

I, Robert Beechey, certify that:

I have reviewed this quarterly report on Form 10-Q of Vermillion, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2018

/s/ Robert Beechey

Robert Beechey

Chief Financial Officer

(Duly Authorized Officer, Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 vrml-20180930xex32_1.htm EX-32.1 Exhibit 32.1

Exhibit 32.1

Certification of the Chief Executive Officer and Senior Vice President, Finance and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350,

as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

with Respect to the Quarterly Report on Form 10-Q

for the Period Ended September 30, 2018

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Vermillion, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of such officer’s knowledge, that:

The Company’s quarterly report on Form 10-Q for the period ended September 30, 2018, (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 8, 2018	/s/ Valerie B. Palmieri
	Valerie B. Palmieri President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)

Date: November 8, 2018	/s/ Robert Beechey
	Robert Beechey Chief Financial Officer (Duly Authorized Officer, Principal Financial Officer and Principal Accounting Officer)

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-Q or as a separate disclosure document of the Company or the certifying officers.

GRAPHIC 5 vrml-20180930x10qg001.jpg GRAPHIC begin 644 vrml-20180930x10qg001.jpg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

EX-101.INS 6 vrml-20180930.xml EX-101.INS 0000926617 us-gaap:CommonClassAMember 2014-12-01 2014-12-31 0000926617 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-09-30 0000926617 us-gaap:CommonClassAMember 2018-01-01 2018-09-30 0000926617 vrml:TrumbullConnecticutFacilityMember 2018-01-01 2018-09-30 0000926617 2017-02-17 0000926617 2017-12-23 2017-12-23 0000926617 us-gaap:EmployeeStockOptionMember vrml:StockOptionPlanTwentyTenMember vrml:ExercisePriceFMember vrml:CertainOfficersAndEmployeesMember 2018-01-01 2018-09-30 0000926617 us-gaap:EmployeeStockOptionMember vrml:StockOptionPlanTwentyTenMember vrml:ExercisePriceEMember vrml:CertainOfficersAndEmployeesMember 2018-01-01 2018-09-30 0000926617 vrml:StockOptionPlanTwentyTenMember 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:BoardOfDirectorsMember 2018-01-01 2018-09-30 0000926617 us-gaap:EmployeeStockOptionMember vrml:StockOptionPlanTwentyTenMember vrml:ExercisePriceFMember vrml:CertainOfficersAndEmployeesMember 2018-09-30 0000926617 us-gaap:EmployeeStockOptionMember vrml:StockOptionPlanTwentyTenMember vrml:ExercisePriceEMember vrml:CertainOfficersAndEmployeesMember 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember 2018-07-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:CertainConsultantsMember 2018-07-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember 2018-01-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:CertainConsultantsMember 2018-01-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember vrml:VestingPercentageDateCMember 2018-07-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember vrml:VestingPercentageDateBMember 2018-07-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember vrml:VestingPercentageDateMember 2018-01-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember vrml:VestingPercentageDateCMember 2018-01-01 2018-09-30 0000926617 us-gaap:RestrictedStockMember vrml:StockOptionPlanTwentyTenMember vrml:NonEmployeeDirectorsMember vrml:VestingPercentageDateBMember 2018-01-01 2018-09-30 0000926617 us-gaap:EmployeeStockOptionMember vrml:StockOptionPlanTwentyTenMember vrml:CertainOfficersAndEmployeesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-09-30 0000926617 us-gaap:ProductMember us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0000926617 us-gaap:ProductMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000926617 vrml:FormerSeniorVicePresidentFinanceAndChiefAccountingOfficerMember 2018-01-01 2018-09-30 0000926617 2017-08-31 2017-08-31 0000926617 vrml:DecdMember 2016-04-15 2016-04-15 0000926617 us-gaap:SeriesBPreferredStockMember 2018-04-17 2018-04-17 0000926617 us-gaap:CommonClassAMember 2018-04-17 2018-04-17 0000926617 2018-04-17 2018-04-17 0000926617 us-gaap:CommonClassAMember 2017-08-31 2017-08-31 0000926617 us-gaap:CommonClassAMember 2017-02-17 2017-02-17 0000926617 2017-02-17 2017-02-17 0000926617 us-gaap:SeriesBPreferredStockMember 2018-04-13 0000926617 vrml:TrumbullConnecticutFacilityMember 2015-10-01 2015-10-31 0000926617 us-gaap:AccountingStandardsUpdate201409Member 2018-09-30 0000926617 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-09-30 0000926617 vrml:TrumbullConnecticutFacilityMember 2018-09-30 0000926617 vrml:TrumbullConnecticutFacilityMember 2015-10-31 0000926617 vrml:AustinTexasFacilityMember 2018-01-01 2018-09-30 0000926617 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0000926617 vrml:DecdMember 2018-01-01 2018-09-30 0000926617 vrml:DecdMember 2016-03-22 2016-03-22 0000926617 vrml:DecdMember 2016-03-22 0000926617 us-gaap:ServiceMember 2018-07-01 2018-09-30 0000926617 us-gaap:ProductMember 2018-07-01 2018-09-30 0000926617 us-gaap:ServiceMember 2018-01-01 2018-09-30 0000926617 us-gaap:ProductMember 2018-01-01 2018-09-30 0000926617 us-gaap:ServiceMember 2017-07-01 2017-09-30 0000926617 us-gaap:ProductMember 2017-07-01 2017-09-30 0000926617 2017-07-01 2017-09-30 0000926617 us-gaap:ServiceMember 2017-01-01 2017-09-30 0000926617 us-gaap:ProductMember 2017-01-01 2017-09-30 0000926617 us-gaap:SeriesBPreferredStockMember 2018-06-21 2018-06-21 0000926617 us-gaap:CommonClassAMember 2017-08-31 0000926617 us-gaap:CommonClassAMember 2018-04-13 0000926617 2018-06-21 0000926617 2017-08-31 0000926617 us-gaap:CommonClassAMember 2017-02-17 0000926617 us-gaap:CommonClassAMember 2014-12-31 0000926617 2017-09-30 0000926617 2016-12-31 0000926617 2018-07-01 2018-09-30 0000926617 2017-01-01 2017-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-07-01 2018-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-07-01 2018-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-07-01 2018-09-30 0000926617 us-gaap:CostOfSalesMember vrml:EmployeeStockBasedCompensationMember 2018-07-01 2018-09-30 0000926617 vrml:EmployeeStockBasedCompensationMember 2018-07-01 2018-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2018-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0000926617 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-01-01 2018-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-01-01 2018-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember vrml:EmployeeStockBasedCompensationMember 2018-01-01 2018-09-30 0000926617 us-gaap:CostOfSalesMember vrml:EmployeeStockBasedCompensationMember 2018-01-01 2018-09-30 0000926617 vrml:EmployeeStockBasedCompensationMember 2018-01-01 2018-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000926617 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember vrml:EmployeeStockBasedCompensationMember 2017-07-01 2017-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember vrml:EmployeeStockBasedCompensationMember 2017-07-01 2017-09-30 0000926617 us-gaap:CostOfSalesMember vrml:EmployeeStockBasedCompensationMember 2017-07-01 2017-09-30 0000926617 vrml:EmployeeStockBasedCompensationMember 2017-07-01 2017-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember 2017-07-01 2017-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0000926617 us-gaap:CostOfSalesMember 2017-07-01 2017-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember vrml:EmployeeStockBasedCompensationMember 2017-01-01 2017-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember vrml:EmployeeStockBasedCompensationMember 2017-01-01 2017-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember vrml:EmployeeStockBasedCompensationMember 2017-01-01 2017-09-30 0000926617 us-gaap:CostOfSalesMember vrml:EmployeeStockBasedCompensationMember 2017-01-01 2017-09-30 0000926617 vrml:EmployeeStockBasedCompensationMember 2017-01-01 2017-09-30 0000926617 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-09-30 0000926617 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0000926617 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0000926617 us-gaap:CostOfSalesMember 2017-01-01 2017-09-30 0000926617 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-09-30 0000926617 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-30 0000926617 2018-09-30 0000926617 2017-12-31 0000926617 2018-10-31 0000926617 2018-01-01 2018-09-30 vrml:employee xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q3 2018 2018-09-30 10-Q 0000926617 75382684 false Non-accelerated Filer VERMILLION, INC. true vrml

745000

495000

205000

656000

171000

485000

1650000

1741000

399400000

413739000

108000

767000

7000

115000

804000

61000

630000

5000

108000

29000

257000

2000

38000

275000

21000

216000

38000

93000

657000

4000

85000

895000

69000

727000

4000

95000

35000

245000

2000

14000

271000

22000

233000

2000

14000

7971860

7414053

7497000

13474000

6305000

12773000

<div> <div style="margin-left:0pt;margin-right:0pt;"> Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2017 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 13, 2018 (the “2017 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. </div> </div>

5242000

7752000

5539000

11760000

2510000

6221000

2.00

1.80

1.00

100

2810338

<div> <div style="margin-left:0pt;margin-right:0pt;"> 3.   COMMITMENTS AND CONTINGENCIES Development Loan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD.  Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations.  The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026.  As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property.  The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender.  Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”).  Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date,  or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan.   An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement.  The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used by ASPiRA IVD is located in Trumbull, Connecticut. The Austin, Texas lease includes an aggregate annual base rent of $86,000 and annual estimated common area charges, taxes and insurance of $46,000 and expires on January 31, 2019.     In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000. The term of the lease is five years beginning after the initial date of occupancy in January 2016 and a rent abatement period of five months. The lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $95,000.   Building rent for the three months ended September 30, 2018 and 2017 totaled $66,000 for each period. Building rent for the nine months ended September 30, 2018 and 2017 totaled $199,000 and $189,000, respectively. Non-cancelable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property. Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500. Royalty expense for the three months ended September 30, 2018 and 2017 totalled $30,000 for each period. Royalty expense for the nine months ended September 30, 2018 and 2017 totalled $78,000 and $94,000, respectively.    </div> </div>

0.001

150000000

3747125

3796818

60036017

10000000

75382684

60036017

75382684

4296000

60000

75000

4496000

50000

5000000

2200000

1345000

855000

779000

495000

284000

2389000

1538000

851000

778000

477000

301000

<div> <div style="margin-left:0pt;margin-right:0pt;"> 2.   AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED In March 2015, the Company entered into a commercial agreement with Quest Diagnostics, <a name="_cp_text_1_39"></a>Incorporated (“Quest Diagnostics”). Pursuant to this agreement, <a name="_cp_text_1_40"></a>all OVA1 U.S. testing services for Quest Diagnostics <a name="_cp_text_1_42"></a>customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2019 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. </div> </div>

0.02

2026-04-15

P10Y

599000

527000

-0.15

-0.06

-0.13

-0.12

-0.04

-4000

-11000

3825000

1177000

3780000

1167000

123000

-80000

-258000

-4000

-401000

-159000

-54000

-49000

62000

13000

-312000

-228000

-32000

-10000

-25000

-6000

36000

33000

102000

115000

2019-01-31

596000

P5Y

4090000

3764000

7497000

13474000

2609000

2424000

4000000

2000000

1481000

1340000

8543000

13348000

-56000

-58000

-5977000

-7069000

-7542000

-2509000

-8551000

-8536000

-15000

-2652000

-8484000

-3451000

-8551000

-2652000

500000

<div> <div style="margin-left:0pt;margin-right:0pt;"> Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements.  In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting.  This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards.    This amendment is effective for annual periods after December 15, 2018.  The Company is currently evaluating the impact of adoption of this standard. In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). This guidance is intended to make leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 will be effective for interim and annual periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited and early adoption is permitted. The Company expects to adopt this standard beginning in 2019. Currently, our only significant leases are our two office leases.The Company is still evaluating the effect adoption will have on our financial statements. We expect to complete our evaluation during the fourth quarter. In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.   </div> </div>

7624000

2419000

8251000

2639000

-7501000

-2499000

-8509000

-8494000

-15000

-2643000

189000

66000

199000

66000

<div> <div style="margin-left:0pt;margin-right:0pt;"> 1.   ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company<a name="_cp_text_1_15"></a>,” “we” or “our”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $404,104,000 at September 30, 2018. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2018. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position will be sufficient to meet the Company’s working capital needs for at least the next 12 months. As discussed in Note 4, on April 17, 2018, the Company completed two public offerings, pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses.   As discussed in Note 4, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,577,000 after deducting offering expenses. As discussed in Note 4, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses. As discussed in Note 3, in March 2016, the Company entered into an agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. <a name="S163573625"></a>The loan may be prepaid at any time without premium or penalty. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2017 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 13, 2018 (the “2017 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Significant Accounting and Reporting Policies <p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"> Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which it adopted on January 1, 2018 using the modified retrospective method. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. Product Revenue Prior to January 1, 2018, the Company recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC 606, all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year.       The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the three and nine months ended September 30, 2018. Under the modified retrospective implementation method, the Company recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all open OVA1 and Overa tests performed prior to January 1, 2018 as if revenue had been recognized under ASC 606.  The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time. The following tables show the impact of adoption to our consolidated statement of operations and balance sheet: <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Nine Months Ended September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands, except per share amounts) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Product revenue </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,979  </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,994  </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Operating loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,509) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,494) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Net loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,551) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,536) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Net loss per share, basic and diluted </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.13) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.12) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">  - </td> </tr> </table></div> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> Assets: </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accounts receivable </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">656  </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">171  </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Stockholders' equity: </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accumulated deficit </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,104) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,589) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> </table></div> ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above tables. Other Practical Expedients      The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.     The Company expenses sales commissions when incurred because the amortization period would have been one year or less.  These costs are recorded within sales and marketing expenses. Service Revenue The Company’s service revenue is generated by performing IVD trial services for third-party customers. Application of the modified retrospective method did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption.  Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements.  In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting.  This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards.    This amendment is effective for annual periods after December 15, 2018.  The Company is currently evaluating the impact of adoption of this standard. In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (“ASU 2016-2”). This guidance is intended to make leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 will be effective for interim and annual periods beginning after December 15, 2018. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited and early adoption is permitted. The Company expects to adopt this standard beginning in 2019. Currently, our only significant leases are our two office leases.The Company is still evaluating the effect adoption will have on our financial statements. We expect to complete our evaluation during the fourth quarter. In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.   </div> </div>

11000

29000

-9000

-17000

-3000

32000

86000

57500

56000

58000

0.001

5000000

50000

459000

242000

8990000

4496000

5127000

3577000

13500000

8992000

4496000

2000000

29000

3577000

1181000

701000

53925

25000

29000

136000

138000

685000

192000

425000

129000

-396053000

-404104000

-404589000

485000

2323000

2195000

128000

699000

657000

42000

2131000

1979000

152000

1994000

-15000

774000

739000

35000

94000

30000

78000

30000

<div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> Three Months Ended September 30, </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> Nine Months Ended September 30, </td> </tr> <tr> <td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands) </td> <td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Cost of revenue </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">69  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">61  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">  - </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Sales and marketing </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">95  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">108  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">233  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">216  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">727  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">630  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">271  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">275  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">895  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">804  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> </tr> </table></div> </div> </div>

3114000

1050000

4046000

1343000

997000

839000

0.25

0.5

0.32

0.68

23350

398400

16816

27871

1.11

0.90

35000

12122983

934000

125000

<div> <div style="margin-left:0pt;margin-right:0pt;"> 4.   STOCKHOLDERS’ EQUITY 2018 Offerings     On April 13, 2018, the Company entered into two underwriting agreements (each, an “Underwriting Agreement”) with Piper Jaffray & Co., as the sole underwriter (the “Underwriter”), in connection with separate but concurrent public offerings of the Company’s securities. Pursuant to the first Underwriting Agreement, the Company agreed to issue and sell an aggregate of 10,000,000 shares of Vermillion common stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $1.00 per share (the “Common Stock Offering”). Under this Underwriting Agreement, the Company granted the Underwriter an option to purchase up to an additional 1,500,000 shares of Vermillion common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The Underwriter did not exercise this option. The Common Stock Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $8,992,000. Pursuant to the second Underwriting Agreement, the Company agreed to issue and sell an aggregate of 50,000 shares of Vermillion Series B Convertible Preferred Stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $100.00 per share (the “Series B Offering”).  The Series B Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $4,496,000. Upon obtaining Company stockholder approval at the annual meeting of Company stockholders on June 21, 2018, each of the 50,000 shares of Vermillion Series B Convertible Preferred Stock was automatically converted into shares of Vermillion common stock, at a conversion rate of 100 shares of Vermillion common stock per one share of Vermillion Series B Convertible Preferred Stock, including shares issuable pursuant to customary anti-dilution provisions. 2017 Warrant Repricing and Exercise       <a name="T3231985711"></a> In December 2014, the Company issued warrants to purchase up to an aggregate of 4,166,659 shares of Vermillion common stock at an exercise price of $2.00 per share in conjunction with a December 2014 private placement of Vermillion common stock.   On August 31, 2017, certain holders of these warrants exercised warrants to purchase 3,796,818 shares of Vermillion common stock in consideration for the Company agreeing to reduce the exercise price to $1.00 per share of Vermillion common stock. The remaining 369,841 unexercised warrants expired by their original terms on December 23, 2017.  The Company issued 3,796,818 shares of Vermillion common stock and received $3,796,818 in aggregate gross proceeds (approximately $3,577,000 net of transaction costs). The incremental non-cash fair value of approximately $942,000 from the modification of the warrants was calculated using the Black-Scholes model and recorded as a deemed dividend to the warrant holders within stockholders’ equity. 2017 Private Placement        On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of Vermillion common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,127,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period. The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stock is approximately $4,296,000. 2010 Stock Incentive Plan The Company’s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. <a name="_cp_text_4_18"></a>Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 12,122,983 shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan. Stock-Based Compensation During the three months ended September 30, 2018, the Company awarded Vermillion’s non-employee directors an aggregate of 27,871 shares of restricted stock under the 2010 Plan having a fair value of approximately $35,000. The vesting of these shares of restricted stock is as follows: 32% on September 1, 2018, and 68% on December 1, 2018. The Company also awarded a certain consultant 16,816 shares of restricted stock under the 2010 Plan having a fair value of approximately $13,000.   During the nine months ended September 30, 2018, the Company awarded Vermillion’s non-employee directors an aggregate of 398,400 shares of restricted stock under the 2010 Plan having a fair value of approximately $442,000. The vesting of these shares of restricted stock is as follows: 50% on June 1, 2018, 25% on September 1, 2018 and 25% on December 1, 2018. 35,000 of those shares of restricted stock were forfeited upon the departure of a board member in June. The Company also awarded certain consultants 23,350 shares of restricted stock under the 2010 Plan having a fair value of approximately $23,000.   During the nine months ended September 30, 2018, the Company granted certain officers and employees options to purchase an aggregate of 934,000 shares of Vermillion common stock with an exercise price of $1.11 per share and 125,000 shares of Vermillion common stock with an exercise price of $0.90 per share. These stock options vest 25% on each of the four anniversaries of the vesting commencement date for each such stock option.  The allocation of employee stock-based compensation expense by functional area for the three and nine months ended September 30, 2018 and 2017 was as follows:   <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> Three Months Ended September 30, </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"> Nine Months Ended September 30, </td> </tr> <tr> <td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands) </td> <td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2017 </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> 2017 </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Cost of revenue </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">21  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">69  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">61  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">  - </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Sales and marketing </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">95  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">108  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">233  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">216  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">727  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">630  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.86%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">271  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">275  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">895  </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">804  </td> </tr> <tr> <td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.86%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> </tr> </table></div> </div> </div>

1.40

185000

188000

3407000

9710000

23000

442000

13000

35000

942000

55909788

57455786

68288216

75306074

3796818 369841 P5Y 2000000 0.05 40 942000 804000 <div> <div style="margin-left:0pt;margin-right:0pt;"> Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $404,104,000 at September 30, 2018. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2018. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations.  However, management believes that the current working capital position will be sufficient to meet the Company’s working capital needs for at least the next 12 months. As discussed in Note 4, on April 17, 2018, the Company completed two public offerings, pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses.   As discussed in Note 4, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,577,000 after deducting offering expenses. As discussed in Note 4, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of Vermillion common stock for net proceeds of approximately $5,127,000 after deducting offering expenses. As discussed in Note 3, in March 2016, the Company entered into an agreement (the “Loan Agreement”) pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. <a name="S163573625"></a>The loan may be prepaid at any time without premium or penalty. </div> </div> 3796818 P5M 95000 46000 <div> <div style="margin-left:0pt;margin-right:0pt;"> Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company<a name="_cp_text_1_15"></a>,” “we” or “our”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. </div> </div> 150 0.04 0.07 0.07 0.125 <div> <div style="margin-left:0pt;margin-right:0pt;"> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Nine Months Ended September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands, except per share amounts) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Product revenue </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,979  </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,994  </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Operating loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,509) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,494) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Net loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,551) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,536) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Net loss per share, basic and diluted </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.13) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.12) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">  - </td> </tr> </table></div> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> Assets: </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accounts receivable </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">656  </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">171  </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Stockholders' equity: </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accumulated deficit </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,104) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,589) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> </table></div> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> Significant Accounting and Reporting Policies <p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"> Revenue Recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which it adopted on January 1, 2018 using the modified retrospective method. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods and services. Product Revenue Prior to January 1, 2018, the Company recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC 606, all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year.       The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the three and nine months ended September 30, 2018. Under the modified retrospective implementation method, the Company recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all open OVA1 and Overa tests performed prior to January 1, 2018 as if revenue had been recognized under ASC 606.  The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time. The following tables show the impact of adoption to our consolidated statement of operations and balance sheet: <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Nine Months Ended September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands, except per share amounts) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Product revenue </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,979  </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,994  </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Operating loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,509) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,494) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Net loss </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,551) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,536) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Net loss per share, basic and diluted </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.13) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.12) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">  - </td> </tr> </table></div> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td colspan="10" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> September 30, 2018 </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="8" valign="middle" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Impact of changes in accounting policies </td> </tr> <tr> <td valign="top" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> (in thousands) </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> As Reported </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Balances without adoption of ASC 606 </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;">   </td> <td colspan="2" valign="middle" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1.5pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;height:12.75pt;padding:0pt;"> Effect of Change Higher/(Lower) </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"> Assets: </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accounts receivable </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">656  </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">171  </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"> Stockholders' equity: </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:45.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> Accumulated deficit </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:14.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,104) </td> <td valign="middle" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(404,589) </td> <td valign="middle" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">   </td> <td valign="middle" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"> $ </td> <td valign="middle" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">485  </td> </tr> </table></div> ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s condensed consolidated statement of cash flows, as reflected in the above tables. Other Practical Expedients      The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.     The Company expenses sales commissions when incurred because the amortization period would have been one year or less.  These costs are recorded within sales and marketing expenses. Service Revenue The Company’s service revenue is generated by performing IVD trial services for third-party customers. Application of the modified retrospective method did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption.  Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements. </div> </div> 1.00 100.00 1500000 4166659 Cost of revenue $35, $29, $93, $108 General and administrative $245, $257, $657, $767 Research and development $2, 2, $4, $7 Sales and marketing $14, $38, $85, $115

EX-101.SCH 7 vrml-20180930.xsd EX-101.SCH 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Condensed Consolidated Statements Of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Agreements With Quest Diagnostics Incorporated link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Summary Of The Impact Of Adoption ASC 606 On Financials) (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Commitments And Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vrml-20180930_cal.xml EX-101.CAL EX-101.DEF 9 vrml-20180930_def.xml EX-101.DEF EX-101.LAB 10 vrml-20180930_lab.xml EX-101.LAB Document And Entity Information [Abstract] Document And Entity Information [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Entity Small Business Entity Emerging Growth Company Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets [Abstract] Assets Assets Assets Current [Abstract] Current assets: Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash and cash equivalents Accounts Receivable Net Current Accounts receivable Accounts receivable, net Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Inventory, Net Inventories Assets Current Total current assets Property Plant And Equipment Net Property and equipment, net Other Assets, Noncurrent Other assets Assets Total Total assets Liabilities And Stockholders Equity [Abstract] Liabilities and Stockholders' Equity Liabilities Current [Abstract] Current liabilities: Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued liabilities Short Term Borrowings Short-term debt Other Liabilities, Current Other current liabilities Liabilities Current Total current liabilities Non-current liabilities: Long-term Debt, Excluding Current Maturities Long-term debt Liabilities Total liabilities Commitments And Contingencies Commitments and contingencies (Note 3) Stockholders' equity: Stockholders' equity: Common Stock Value Common stock, par value $0.001 per share, 150,000,000 shares authorized at September 30, 2018 and December 31, 2017; 75,382,684 and 60,036,017 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common stock value Additional Paid In Capital Additional paid-in capital Retained Earnings Accumulated Deficit Accumulated deficit Stockholders Equity Total stockholders' equity Liabilities And Stockholders Equity Total liabilities and stockholders' equity Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Common Stock Par Or Stated Value Per Share Common stock, par value Par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Condensed Consolidated Statements Of Operations [Abstract] Revenues [Abstract] Revenue: Revenues Revenue Cost Of Goods Sold [Abstract] Cost of revenue: Cost Of Goods And Services Sold Cost of revenue Gross Profit Gross profit (loss) Operating Expenses [Abstract] Operating expenses: Research And Development Expense Research and development Selling And Marketing Expense Sales and marketing General And Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income Loss Operating loss Loss from operations Investment Income Interest Interest income (expense), net Nonoperating Income Expense Other income (expense), net Net Income Loss Net loss Net loss Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Deemed dividend on warrant repricing Incremental non-cash fair value of warrants Net Income Loss Available To Common Stockholders Basic Net loss attributable to common stockholders Earnings Per Share Basic And Diluted Net loss per share attributable to common stockholders - basic and diluted Net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Weighted average common shares used to compute basic and diluted net loss per common share Income Statement Location [Axis] Income Statement Location [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Research And Development Expense [Member] Research And Development [Member] Selling And Marketing Expense [Member] Sales And Marketing [Member] General And Administrative Expense [Member] General And Administrative [Member] Allocated Share Based Compensation Expense Stock-based compensation expense Condensed Consolidated Statements Of Cash Flows [Abstract] Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depletion And Amortization Depreciation and amortization Share Based Compensation Stock-based compensation expense Gain Loss On Sale Of Property Plant Equipment Loss on sale and disposal of property and equipment Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Increase (Decrease) in Inventories Inventories Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable, accrued liabilities and other liabilities Increase Decrease In Deferred Revenue Deferred revenue Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities: Payments To Acquire Property Plant And Equipment Purchase of property and equipment Net Cash Provided By Used In Investing Activities Net cash used in investing activities Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities: Proceeds From Issuance Of Private Placement Proceeds from private placement offering of common stock, net of issuance costs Proceeds from issuance of private placement Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from public offering of preferred stock, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from public offering of common stock, net of issuance costs Proceeds from Issuance of Warrants Proceeds from exercise of common stock from exercise of warrants, net of issuance costs Proceeds from Lines of Credit DECD initial disbursement Proceeds from issuance of DECD loan, net of issuance costs Repayments of Debt Principal repayment of DECD loan Repayments of Debt and Capital Lease Obligations Repayment of capital lease obligations Proceeds From Stock Options Exercised Proceeds from issuance of common stock from exercise of stock options Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Cash And Cash Equivalents Period Increase Decrease Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid Net Cash paid during the period for interest Supplemental disclosure of non-cash investing and financing activities: Conversion of Stock, Amount Converted 50,000 shares of convertible preferred stock converted to 5,000,000 shares of common stock, net of issuance costs Deemed Dividend On Warrant Repricing Deemed Dividend On Warrant Repricing Deemed dividend on warrant repricing Conversion of Stock, Shares Converted Shares converted Conversion of Stock, Shares Issued Conversion of new shares Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract] Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Organization, Basis Of Presentation And Significant Accounting And Reporting Policies Agreements With Quest Diagnostics Incorporated [Abstract] Debt Disclosure [Text Block] Agreements With Quest Diagnostics Incorporated Commitments And Contingencies [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments And Contingencies Compensation And Employee Benefit Plans [Text Block] Stockholders' Equity Loss Per Share [Abstract] Earnings Per Share [Text Block] Loss Per Share Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Organization policy. Organization Policy [Text Block] Organization Going Concern [Policy Text Block] Going Concern [Policy Text Block] Liquidity Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Significant Accounting And Reporting Policies [Policy Text Block] Significant Accounting And Reporting Policies [Policy Text Block] Significant Accounting and Reporting Policies Other Significant Accounting And Reporting Policies Policy [Text Block] Recent Accounting Pronouncements Revenue, Initial Application Period Cumulative Effect Transition [Table Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table Text Block] Summary Of The Impact Of Adoption ASC 606 On Financials Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Allocation of Stock-Based Compensation Expense by Functional Area Basis Of Presentation And Significant Accounting Policies [Table] Basis Of Presentation And Significant Accounting Policies [Table] Basis Of Presentation And Significant Accounting Policies [Table] Lender Name [Axis] Line Of Credit Facility Lender [Domain] Line of Credit Facility, Lender [Domain] DECD [Member] Decd [Member] DECD [Member] Organization Consolidation And Summary Of Significant Accounting Policies [Line Items] Organization Consolidation And Summary Of Significant Accounting Policies [Line Items] Organization Consolidation And Summary Of Significant Accounting Policies [Line Items] Proceeds from Issuance or Sale of Equity Proceeds from public offering New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets One time adjustment Line of Credit Facility, Maximum Borrowing Capacity DECD maximum borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity DECD remaining borrowing capacity Asset Impairment Charges Impairment losses Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Debt Instrument, Interest Rate, Stated Percentage Fixed rate per annum Debt Instrument, Maturity Date Maturity date Debt Instrument, Amount Eligible For Forgiveness Debt Instrument, Amount Eligible For Forgiveness Amount eligible for forgiveness Debt Instrument, Debt Covenant, Job Creation, Number Of Employees Debt Instrument, Debt Covenant, Job Creation, Number Of Employees Job creation, number of employees Debt Instrument, Term Debt, maturity term Debt Instrument, Covenant Noncompliance Penalty Debt Instrument, Covenant Noncompliance Penalty Debt penalty percentage Payments For Rent Annual base rent Operating Leases, Other Occupancy Costs Operating Leases Other Occupancy Costs Annual estimated common area charges, taxes and insurance Lease Expiration Date 1 Lease expiration date Leasehold Improvements, Gross Leasehold improvements Lessee Leasing Arrangements, Operating Leases, Term of Contract Lease term Lessee Leasing Arrangements, Operating Leases, Rent Abatement Period Lessee Leasing Arrangements, Operating Leases, Rent Abatement Period Rent abatement period Operating Leases, Rent Expense, Net Operating leases rental expense Percentage Of Royalty Paid Percentage Of Royalty Paid Percent of royalty paid Payments for Royalties Minimum royalty payment Royalty Expense Royalty expense Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Option Plan 2010 [Member] Stock Option Plan Twenty Ten [Member] 2010 Stock Incentive Plan [Member] Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Title of Individual with Relationship to Entity [Domain] Non-Employee Directors [Member] Non Employee Directors [Member] Non-Employee Directors [Member] Certain Consultants [Member] Certain Consultants [Member] Certain Consultants [Member] Certain Officers And Employees [Member] Certain Officers And Employees [Member] Certain Officers And Employees [Member] Board Of Directors [Member] Board Of Directors [Member] Board Of Directors [Member] Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price E [Member] Exercise Price E [Member] $1.11 [Member] Exercise Price F [Member] Exercise Price F [Member] $0.90 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Warrants Issued In Connection With Private Placement Warrants Issued In Connection With Private Placement Warrants issued in connection with private placement Class of Warrant or Right, Warrants Exercised Class of Warrant or Right, Warrants Exercised Warrants exercised Class Of Warrant Or Right, Warrants Unexercised Class Of Warrant Or Right, Warrants Unexercised Warrants unexercised Shares Issued, Price Per Share Price per share Price Of Shares To Be Issued Under Warrants Price Of Shares To Be Issued Under Warrants Issued a warrant to purchase common stock with a cost Underwriting Commitments, Per Share Underwriting Commitments, Per Share Underwriting agreement, per share Underwriting Commitments, Shares Underwriting Commitments, Shares Underwriting agreement Class Of Warrant Or Right Outstanding Warrants outstanding to purchase shares Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercise price of warrants Represents fair value of warrants issued. Fair Value Of Warrants Issued Fair value of warrants issued Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Common stock issuable per preferred share Gross proceeds from issuance of private placement. Gross Proceeds from issuance of private placement Gross proceeds from issuance of private placement Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Granted Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares available for grant Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Restricted shares granted Stock Issued During Period Value Restricted Stock Award Gross Fair value of restricted share units Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Restricted shares forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Stock options granted, average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting percentage EX-101.PRE 11 vrml-20180930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	0000926617
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	vrml
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		75,382,684

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 11,760,000	$ 5,539,000
Accounts receivable, net	656,000	205,000
Prepaid expenses and other current assets	242,000	459,000
Inventories	115,000	102,000
Total current assets	12,773,000	6,305,000
Property and equipment, net	701,000	1,181,000
Other assets		11,000
Total assets	13,474,000	7,497,000
Current liabilities:
Accounts payable	495,000	745,000
Accrued liabilities	1,741,000	1,650,000
Short-term debt	188,000	185,000
Other current liabilities		29,000
Total current liabilities	2,424,000	2,609,000
Non-current liabilities:
Long-term debt	1,340,000	1,481,000
Total liabilities	3,764,000	4,090,000
Commitments and contingencies (Note 3)
Stockholders' equity:
Common stock, par value $0.001 per share, 150,000,000 shares authorized at September 30, 2018 and December 31, 2017; 75,382,684 and 60,036,017 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	75,000	60,000
Additional paid-in capital	413,739,000	399,400,000
Accumulated deficit	(404,104,000)	(396,053,000)
Total stockholders' equity	9,710,000	3,407,000
Total liabilities and stockholders' equity	$ 13,474,000	$ 7,497,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Condensed Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	75,382,684	60,036,017
Common stock, shares outstanding	75,382,684	60,036,017

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Revenue:

Revenue

$ 774

$ 699

$ 2,131

$ 2,323

Cost of revenue:

Cost of revenue

^[1]

778

779

2,389

2,200

Gross profit (loss)

(4)

(80)

(258)

123

Operating expenses:

Research and development

^[2]

129

192

425

685

Sales and marketing

^[3]

1,343

1,050

4,046

3,114

General and administrative

^[4]

1,167

1,177

3,780

3,825

Total operating expenses

2,639

2,419

8,251

7,624

Loss from operations

(2,643)

(2,499)

(8,509)

(7,501)

Interest income (expense), net

(6)

(10)

(25)

(32)

Other income (expense), net

(3)

(17)

(9)

Net loss

(2,652)

(2,509)

(8,551)

(7,542)

Deemed dividend on warrant repricing

(942)

Net loss attributable to common stockholders

$ (2,652)

$ (3,451)

$ (8,551)

$ (8,484)

Net loss per share attributable to common stockholders - basic and diluted

$ (0.04)

$ (0.06)

$ (0.13)

$ (0.15)

Weighted average common shares used to compute basic and diluted net loss per common share

75,306,074

57,455,786

68,288,216

55,909,788

Product [Member]

Revenue:

Revenue

$ 739

$ 657

$ 1,979

$ 2,195

Cost of revenue:

Cost of revenue

^[1]

477

495

1,538

1,345

Service [Member]

Revenue:

Revenue

152

128

Cost of revenue:

Cost of revenue

^[1]

$ 301

$ 284

$ 851

$ 855

[1]	Cost of revenue $35, $29, $93, $108
[2]	Research and development $2, 2, $4, $7
[3]	Sales and marketing $14, $38, $85, $115
[4]	General and administrative $245, $257, $657, $767

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cost Of Revenue [Member]
Stock-based compensation expense	$ 35	$ 29	$ 93	$ 108
Research And Development [Member]
Stock-based compensation expense	2	2	4	7
Sales And Marketing [Member]
Stock-based compensation expense	14	38	85	115
General And Administrative [Member]
Stock-based compensation expense	$ 245	$ 257	$ 657	$ 767

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (8,551,000)	$ (7,542,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	527,000	599,000
Stock-based compensation expense	839,000	997,000
Loss on sale and disposal of property and equipment	11,000	4,000
Changes in operating assets and liabilities:
Accounts receivable	49,000	54,000
Prepaid expenses and other assets	228,000	312,000
Inventories	(13,000)	(62,000)
Accounts payable, accrued liabilities and other liabilities	(159,000)	(401,000)
Deferred revenue		62,000
Net cash used in operating activities	(7,069,000)	(5,977,000)
Cash flows from investing activities:
Purchase of property and equipment	(58,000)	(56,000)
Net cash used in investing activities	(58,000)	(56,000)
Cash flows from financing activities:
Proceeds from private placement offering of common stock, net of issuance costs		5,127,000
Proceeds from public offering of preferred stock, net of issuance costs	4,496,000
Proceeds from public offering of common stock, net of issuance costs	8,990,000
Proceeds from exercise of common stock from exercise of warrants, net of issuance costs		3,577,000
Principal repayment of DECD loan	(138,000)	(136,000)
Repayment of capital lease obligations	(29,000)	(25,000)
Proceeds from issuance of common stock from exercise of stock options	29,000
Net cash provided by financing activities	13,348,000	8,543,000
Net increase in cash and cash equivalents	6,221,000	2,510,000
Cash and cash equivalents, beginning of period	5,539,000	5,242,000
Cash and cash equivalents, end of period	11,760,000	7,752,000
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	33,000	36,000
Supplemental disclosure of non-cash investing and financing activities:
50,000 shares of convertible preferred stock converted to 5,000,000 shares of common stock, net of issuance costs	$ 4,496,000
Deemed dividend on warrant repricing		$ 942,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2018 shares
Condensed Consolidated Statements Of Cash Flows [Abstract]
Shares converted	50,000
Conversion of new shares	5,000,000

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies

9 Months Ended

Sep. 30, 2018

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies

1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES

Organization

Liquidity

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period.

Significant Accounting and Reporting Policies

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which it adopted on January 1, 2018 using the modified retrospective method.

Product Revenue

Under the modified retrospective implementation method, the Company recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all open OVA1 and Overa tests performed prior to January 1, 2018 as if revenue had been recognized under ASC 606. The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time.

The following tables show the impact of adoption to our consolidated statement of operations and balance sheet:



Nine Months Ended September 30, 2018
	Impact of changes in accounting policies
(in thousands, except per share amounts)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Product revenue	$	1,979	$	1,994	$	(15)
Operating loss	$	(8,509)	$	(8,494)	$	(15)
Net loss	$	(8,551)	$	(8,536)	$	(15)
Net loss per share, basic and diluted	$	(0.13)	$	(0.12)	$	-


September 30, 2018
	Impact of changes in accounting policies
(in thousands)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Assets:
Accounts receivable	$	656	$	171	$	485
Stockholders' equity:
Accumulated deficit	$	(404,104)	$	(404,589)	$	485

Other Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Service Revenue

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Agreements With Quest Diagnostics Incorporated	9 Months Ended
Agreements With Quest Diagnostics Incorporated	Sep. 30, 2018
Agreements With Quest Diagnostics Incorporated [Abstract]
Agreements With Quest Diagnostics Incorporated	2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED In March 2015, the Company entered into a commercial agreement with Quest Diagnostics, Incorporated (“Quest Diagnostics”). Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics is continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2019 in exchange for a market value fee. Per the terms of the new commercial agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies	9 Months Ended
Commitments And Contingencies	Sep. 30, 2018
Commitments And Contingencies [Abstract]
Commitments And Contingencies	3. COMMITMENTS AND CONTINGENCIES Development Loan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026. As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”). Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date, or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used by ASPiRA IVD is located in Trumbull, Connecticut. The Austin, Texas lease includes an aggregate annual base rent of $86,000 and annual estimated common area charges, taxes and insurance of $46,000 and expires on January 31, 2019. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000. The term of the lease is five years beginning after the initial date of occupancy in January 2016 and a rent abatement period of five months. The lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $95,000. Building rent for the three months ended September 30, 2018 and 2017 totaled $66,000 for each period. Building rent for the nine months ended September 30, 2018 and 2017 totaled $199,000 and $189,000, respectively. Non-cancelable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property. Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500. Royalty expense for the three months ended September 30, 2018 and 2017 totalled $30,000 for each period. Royalty expense for the nine months ended September 30, 2018 and 2017 totalled $78,000 and $94,000, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders' equity:

Stockholders' Equity

4. STOCKHOLDERS’ EQUITY

2018 Offerings

2017 Warrant Repricing and Exercise

2017 Private Placement

2010 Stock Incentive Plan

Stock-Based Compensation

The allocation of employee stock-based compensation expense by functional area for the three and nine months ended September 30, 2018 and 2017 was as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2018		2017		2018		2017
Cost of revenue	$	22	$	21	$	69	$	61
Research and development		2		-		4		5
Sales and marketing		14		38		95		108
General and administrative		233		216		727		630
Total	$	271	$	275	$	895	$	804

XML 23 R12.htm IDEA: XBRL DOCUMENT

Loss Per Share	9 Months Ended
Loss Per Share	Sep. 30, 2018
Loss Per Share [Abstract]
Loss Per Share	5. LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of shares of Vermillion common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Vermillion common stock outstanding and excludes the effects of 7,414,053 and 7,971,860 potential shares of Vermillion common stock as of September 30, 2018 and 2017, respectively, that are anti-dilutive. Potential shares of Vermillion common stock include incremental shares of Vermillion common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	6. RELATED PARTY TRANSACTIONS On December 18, 2017, the Company entered into a consulting agreement for a term of up to five months with the Company’s former Senior Vice President, Finance and Chief Accounting Officer. Pursuant to the terms of the consulting agreement through May 15, 2018, the consultant provided accounting and finance services related to the transition of financial leadership. The Company agreed to pay $150 per hour for such consulting services. The consultant also remained eligible for payout under the Company’s 2017 Corporate Incentive Plan after he satisfactorily met certain performance obligations as outlined in the consulting agreement. During the nine months ended September 30, 2018, the consultant was paid an aggregate of $53,925 for services provided pursuant to the consulting agreement.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)

9 Months Ended

Sep. 30, 2018

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]

Organization

Liquidity

Basis of Presentation

Significant Accounting and Reporting Policies

Revenue Recognition

The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which it adopted on January 1, 2018 using the modified retrospective method.

Product Revenue

The following tables show the impact of adoption to our consolidated statement of operations and balance sheet:



Nine Months Ended September 30, 2018
	Impact of changes in accounting policies
(in thousands, except per share amounts)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Product revenue	$	1,979	$	1,994	$	(15)
Operating loss	$	(8,509)	$	(8,494)	$	(15)
Net loss	$	(8,551)	$	(8,536)	$	(15)
Net loss per share, basic and diluted	$	(0.13)	$	(0.12)	$	-


September 30, 2018
	Impact of changes in accounting policies
(in thousands)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Assets:
Accounts receivable	$	656	$	171	$	485
Stockholders' equity:
Accumulated deficit	$	(404,104)	$	(404,589)	$	485

Other Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Service Revenue

Recent Accounting Pronouncements

XML 26 R15.htm IDEA: XBRL DOCUMENT

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]

Summary Of The Impact Of Adoption ASC 606 On Financials



Nine Months Ended September 30, 2018
	Impact of changes in accounting policies
(in thousands, except per share amounts)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Product revenue	$	1,979	$	1,994	$	(15)
Operating loss	$	(8,509)	$	(8,494)	$	(15)
Net loss	$	(8,551)	$	(8,536)	$	(15)
Net loss per share, basic and diluted	$	(0.13)	$	(0.12)	$	-


September 30, 2018
	Impact of changes in accounting policies
(in thousands)	As Reported		Balances without adoption of ASC 606		Effect of Change Higher/(Lower)
Assets:
Accounts receivable	$	656	$	171	$	485
Stockholders' equity:
Accumulated deficit	$	(404,104)	$	(404,589)	$	485

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders' equity:

Allocation of Stock-Based Compensation Expense by Functional Area


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2018		2017		2018		2017
Cost of revenue	$	22	$	21	$	69	$	61
Research and development		2		-		4		5
Sales and marketing		14		38		95		108
General and administrative		233		216		727		630
Total	$	271	$	275	$	895	$	804

XML 28 R17.htm IDEA: XBRL DOCUMENT

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Narrative) (Details) - USD ($)					3 Months Ended	9 Months Ended
	Apr. 17, 2018	Aug. 31, 2017	Feb. 17, 2017	Apr. 15, 2016	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Mar. 22, 2016
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit					$ (404,104,000)	$ (404,104,000)		$ (396,053,000)
Proceeds from exercise of common stock from exercise of warrants, net of issuance costs		$ 3,577,000					$ 3,577,000
Proceeds from public offering	$ 13,500,000
Proceeds from issuance of private placement			$ 5,127,000				$ 5,127,000
Impairment losses					0	0
DECD [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
DECD maximum borrowing capacity									$ 4,000,000
DECD initial disbursement				$ 2,000,000
DECD remaining borrowing capacity									$ 2,000,000
Accounting Standards Update 2014-09 [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
One time adjustment					$ 500,000	$ 500,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Summary Of The Impact Of Adoption ASC 606 On Financials) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 774,000	$ 699,000	$ 2,131,000	$ 2,323,000
Operating loss	(2,643,000)	(2,499,000)	(8,509,000)	(7,501,000)
Net loss	$ (2,652,000)	$ (2,509,000)	$ (8,551,000)	$ (7,542,000)
Net loss per share, basic and diluted	$ (0.04)	$ (0.06)	$ (0.13)	$ (0.15)
Assets
Accounts receivable	$ 656,000		$ 656,000		$ 205,000
Stockholders' equity:
Accumulated deficit	(404,104,000)		(404,104,000)		$ (396,053,000)
Balances Without Adoption of ASC 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Operating loss			(8,494,000)
Net loss			$ (8,536,000)
Net loss per share, basic and diluted			$ (0.12)
Assets
Accounts receivable	171,000		$ 171,000
Stockholders' equity:
Accumulated deficit	(404,589,000)		(404,589,000)
Effect of Change Higher/(Lower) [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Operating loss			(15,000)
Net loss			(15,000)
Assets
Accounts receivable	485,000		485,000
Stockholders' equity:
Accumulated deficit	485,000		485,000
Product [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 739,000	$ 657,000	1,979,000	$ 2,195,000
Product [Member] \| Balances Without Adoption of ASC 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue			1,994,000
Product [Member] \| Effect of Change Higher/(Lower) [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue			$ (15,000)

XML 30 R19.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies (Details)			1 Months Ended	3 Months Ended		9 Months Ended
Commitments And Contingencies (Details)	Apr. 15, 2016 USD ($)	Mar. 22, 2016 USD ($)	Oct. 31, 2015 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) employee	Sep. 30, 2017 USD ($)
Commitments And Contingencies [Line Items]
Operating leases rental expense				$ 66,000	$ 66,000	$ 199,000	$ 189,000
Percent of royalty paid						4.00%
Minimum royalty payment						$ 57,500
Royalty expense				$ 30,000	$ 30,000	78,000	$ 94,000
Austin, Texas facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent						86,000
Annual estimated common area charges, taxes and insurance						$ 46,000
Lease expiration date						Jan. 31, 2019
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent			$ 32,000
Annual estimated common area charges, taxes and insurance			95,000
Leasehold improvements			$ 596,000
Lease term				5 years		5 years
Rent abatement period						5 months
DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity		$ 4,000,000
Fixed rate per annum		2.00%
Maturity date		Apr. 15, 2026
Amount eligible for forgiveness		$ 2,000,000
Job creation, number of employees \| employee						40
Debt, maturity term						10 years
Debt penalty percentage						5.00%
DECD initial disbursement	$ 2,000,000
DECD remaining borrowing capacity		$ 2,000,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Narrative) (Details) - USD ($)						1 Months Ended	3 Months Ended		9 Months Ended
Stockholders' Equity (Narrative) (Details) - USD ($)	Jun. 21, 2018	Apr. 17, 2018	Dec. 23, 2017	Aug. 31, 2017	Feb. 17, 2017	Dec. 31, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 13, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued							75,382,684		75,382,684			60,036,017
Warrants exercised				3,796,818
Warrants unexercised			369,841
Par value							$ 0.001		$ 0.001			$ 0.001
Proceeds from issuance of private placement					$ 5,127,000					$ 5,127,000
Proceeds from public offering		$ 13,500,000
Incremental non-cash fair value of warrants								$ 942,000		$ 942,000
Exercise price of warrants				$ 1.00
Fair value of warrants issued					$ 804,000
Common stock value							$ 75,000		$ 75,000			$ 60,000
Preferred stock, shares issued							0		0			0
Preferred stock, par value							$ 0.001		$ 0.001			$ 0.001
Common stock issuable per preferred share	100
Shares converted									50,000
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant							12,122,983		12,122,983
2010 Stock Incentive Plan [Member] \| Non-Employee Directors [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted							27,871		398,400
Fair value of restricted share units							$ 35,000		$ 442,000
2010 Stock Incentive Plan [Member] \| Non-Employee Directors [Member] \| Restricted Stock [Member] \| June 1, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage									50.00%
2010 Stock Incentive Plan [Member] \| Non-Employee Directors [Member] \| Restricted Stock [Member] \| September 1, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage							32.00%		25.00%
2010 Stock Incentive Plan [Member] \| Non-Employee Directors [Member] \| Restricted Stock [Member] \| December 1, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage							68.00%		25.00%
2010 Stock Incentive Plan [Member] \| Certain Consultants [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted							16,816		23,350
Fair value of restricted share units							$ 13,000		$ 23,000
2010 Stock Incentive Plan [Member] \| Certain Officers And Employees [Member] \| Stock Option [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage									25.00%
2010 Stock Incentive Plan [Member] \| Certain Officers And Employees [Member] \| $1.11 [Member] \| Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted									934,000
Stock options granted, average exercise price							$ 1.11		$ 1.11
2010 Stock Incentive Plan [Member] \| Certain Officers And Employees [Member] \| $0.90 [Member] \| Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted									125,000
Stock options granted, average exercise price							$ 0.90		$ 0.90
2010 Stock Incentive Plan [Member] \| Board Of Directors [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares forfeited									35,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued				3,796,818	3,747,125						10,000,000
Warrants issued in connection with private placement						4,166,659
Par value											$ 0.001
Price per share					$ 1.40
Issued a warrant to purchase common stock with a cost					$ 0.125
Underwriting agreement, per share											$ 1.00
Underwriting agreement											1,500,000
Proceeds from issuance of private placement				$ 3,577,000	$ 5,127,000
Proceeds from public offering		8,992,000
Incremental non-cash fair value of warrants				942,000
Warrants outstanding to purchase shares					2,810,338
Exercise price of warrants					$ 1.80	$ 2.00
Common stock value					$ 4,296,000
Gross proceeds from issuance of private placement				$ 3,796,818
Percent of net proceeds of underwriting costs and other offering costs									7.00%
Series B Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriting agreement, per share											$ 100.00
Proceeds from public offering		$ 4,496,000
Preferred stock, shares issued											50,000
Preferred stock, par value											$ 0.001
Percent of net proceeds of underwriting costs and other offering costs									7.00%
Shares converted	50,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 35	$ 29	$ 93	$ 108
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	2	4	7
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	14	38	85	115
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	245	257	657	767
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	271	275	895	804
Employee Stock-Based Compensation [Member] \| Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	22	21	69	61
Employee Stock-Based Compensation [Member] \| Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2		4	5
Employee Stock-Based Compensation [Member] \| Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	14	38	95	108
Employee Stock-Based Compensation [Member] \| General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 233	$ 216	$ 727	$ 630

XML 33 R22.htm IDEA: XBRL DOCUMENT

Loss Per Share (Details) - shares	9 Months Ended
Loss Per Share (Details) - shares	Sep. 30, 2018	Sep. 30, 2017
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	7,414,053	7,971,860

XML 34 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - Former Senior Vice President, Finance And Chief Accounting Officer [Member]	9 Months Ended
	Sep. 30, 2018 USD ($)
Related Party Transaction [Line Items]
Term of consulting agreement	5 years
Payment per hour	$ 150
Payments to related party	$ 53,925

XML 35 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 36 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 105 142 1 true 29 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.vermillion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements Of Operations Statements 4 false false R5.htm 00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical) Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical Condensed Consolidated Statements Of Operations (Parenthetical) Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 00405 - Statement - Condensed Consolidated Statements Of Cash Flows (Parenthetical) Sheet http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements Of Cash Flows (Parenthetical) Statements 7 false false R8.htm 10101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies Sheet http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies Organization, Basis Of Presentation And Significant Accounting And Reporting Policies Notes 8 false false R9.htm 10201 - Disclosure - Agreements With Quest Diagnostics Incorporated Sheet http://www.vermillion.com/role/DisclosureAgreementsWithQuestDiagnosticsIncorporated Agreements With Quest Diagnostics Incorporated Notes 9 false false R10.htm 10301 - Disclosure - Commitments And Contingencies Sheet http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies Commitments And Contingencies Notes 10 false false R11.htm 10401 - Disclosure - Stockholders' Equity Sheet http://www.vermillion.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 10501 - Disclosure - Loss Per Share Sheet http://www.vermillion.com/role/DisclosureLossPerShare Loss Per Share Notes 12 false false R13.htm 10601 - Disclosure - Related Party Transactions Sheet http://www.vermillion.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 20102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy) Sheet http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy) Policies http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies 14 false false R15.htm 30103 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Tables) Sheet http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesTables Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Tables) Tables http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies 15 false false R16.htm 30403 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.vermillion.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.vermillion.com/role/DisclosureStockholdersEquity 16 false false R17.htm 40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Narrative) (Details) Sheet http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesNarrativeDetails Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Narrative) (Details) Details http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesTables 17 false false R18.htm 40102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Summary Of The Impact Of Adoption ASC 606 On Financials) (Details) Sheet http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesSummaryOfImpactOfAdoptionAsc606OnFinancialsDetails Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Summary Of The Impact Of Adoption ASC 606 On Financials) (Details) Details http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesTables 18 false false R19.htm 40301 - Disclosure - Commitments And Contingencies (Details) Sheet http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments And Contingencies (Details) Details http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies 19 false false R20.htm 40401 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://www.vermillion.com/role/DisclosureStockholdersEquityTables 20 false false R21.htm 40402 - Disclosure - Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) Sheet http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfStockBasedCompensationExpenseByFunctionalAreaDetails Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) Details http://www.vermillion.com/role/DisclosureStockholdersEquityTables 21 false false R22.htm 40501 - Disclosure - Loss Per Share (Details) Sheet http://www.vermillion.com/role/DisclosureLossPerShareDetails Loss Per Share (Details) Details http://www.vermillion.com/role/DisclosureLossPerShare 22 false false R23.htm 40601 - Disclosure - Related Party Transactions (Details) Sheet http://www.vermillion.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.vermillion.com/role/DisclosureRelatedPartyTransactions 23 false false All Reports Book All Reports vrml-20180930.xml vrml-20180930.xsd vrml-20180930_cal.xml vrml-20180930_def.xml vrml-20180930_lab.xml vrml-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 41 0000926617-18-000072-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000926617-18-000072-xbrl.zip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
_7WY!ZMR5:LN,XQ1E8;&1Q9CC#9\@9CDF?__02^.B) M"$DYNVCU.[T6(LSA+F73BU8HVU@ZE+9^^O3WOYW_H]W^[>K^#KG<"0/"%'($ MP8JX:+) R*4?C6DTO&Y# 5!GS'#4V((/W:.CCN]3A^UV[&@*RR!D3-D)!YU M^FG+(!;*V1GJ][L_=H]Z_1_1\=G1R=G)!S3^G!)^!B4]NI92.C,28 1F,GG1 MFBDU/^MVGY^?.\_''2ZFP-3K=W_[?/=@Z%H1X=G+1/BT0*[?) S'7E/'D#3KI18PLI+*9$?<$!D7/LD$(/X$4!]7UPI([# X-&[_18 M.Y1OW."&BV!(/!SZT,N?(?8-?"V$E1)T$BI2( A9CB32D+(G(I_WV<3]A>A*!7T_-B-[A(5-B4=Y+W*B9_E7LQB6TG 4:3!]%/P17FA? M.Q/<)X\@ NF'K_>WM@'3)-T'D&I '7#F$@:3&1XD]ZFK)^\5]O7D>)@1HF0+ M4?>BU80A52Y1SR4>9=28 ;.UUT-ME,J#YU0DRLM$L5 423WO+HM:[B4$"2/V MR3S/!9$@W S=';R(N6,2&Z>#?2?T-V#,-*OFB]\F<.T6Q;15CKS1G AC4RTX M*SCMN![5Q363CD8>RN0?$-X&X0&6LQN?/S<&.&.TX_MA,WRU>&3D'_!=Q7<8 MYV+)WTOF7C-%U>(6%GD1&",B0&M1VA'LG6H$$P'Y1\Q<%$E#.7$'P+8*G&,L M@&Y&% 4#&T?1(O>ZD'JR24A%WQ4Z^?Z ]^N$V,; UQ&S+OC6]("JX'OPA9T$ MXZU$HU5'R&0C+1P9Z2@G'N7E'Q"V(3S@04"5&4R8(+ :Z]E! M6-GDMY':,3Q>Q3 GS,S,@K@#9#;('A1W_IAQWR5"7O\9P@YI&:D2"CM 'U8! MRLOX)XJD''"QX7+'I1P3\3"#7&49D4*;'8N352PT-P)V9/@/*-A0N">^7O4A M852+1X&9Q$ZNR%B#SH[.QU5T8DG(B$)Y60>DWBA/-7]7EL'7[\#F&Y"H]([> M)&>%[9!1Y[ />BO_>L03?Z>[H;@#FW]!$M4[?B/_BM0Y^%?#/*S<32KI[&A_ M6$6[+"<[@/76B\$7+'2%\HD,B<+4W^6RL-*5S64^O%G1!'V7*O8]^B[6[>" M;^6 #V$08+$8>;?!'#+-D7?I\KD1(IV/O8\C=D,9AHTT]N7N770#9=8Y\5ME M4;'J6M3CC*#( /TI,0%=/@P0&(%&#&5F'%Q^^]I2A5_6X+ [3]-*TP'*37.= M=5&P!H<=RIHUJ4,L>@TT+WV?.\:,D6=:S6E:F#ISPJ1Y?_VB'\G5XB9DIKJ! M_4M!<&WTM^YAG;>L1(UR;\GT0-R+:.*CPWE=4*R,/HB6N$F M921VG-=61P_H;%:^ M/MQOWF'A:'[[\?[N7/ Y@227R&XB-A&PPEV\3&!\8VD48JT2"3-!O(N6/OK> M3LZW_PX% M:G:>,.A>3S8P>?4Z4YV.E[ET[Z?:YO['K73(W\-JI@=G7S94Q7K=J$P)6<6D M']H9]V8.>!K-7D:FT5&C.L/@"U'@:CP&^;M06I!<.PC)&)3>O.H27\E4UNL- M2E$6K0/*[YN+B**EN3YZ)I4 @EM% IU+MA">P!O(FR]:2H0Z%!HJ")&4NX^& MSPU%?&6#P69 2TQH90C,5(6Z]6?!PWG4B:O.9L IG'!"=$<50Q*?TV;3.P(+ MO!RI&1$CQPGG$'(6 RZ36WK&^#K$>3,##FZ*Q:+,4 _[2-X MH/764THO8^46-F.QF+>Z FQA8/EZ4&6V[3K;9>QJB;TU:6TX+DW1-68V\?4J M Z\X%N[(&U(!SL>%3"99'.NJ6DN-J)B2._#&;T2:%0\BDPZ@4S($;RJJ;B=Y MC_I?U3#@ZEU;,*AAP>"]6' =S'V^(*3\"XBB)35I]VW1"XPTE0165X=<+UE0 MWO:>-+ZQ:'SS7C2^P51\PWX(0:P8P1.U;02[C7%1C4*LET5TELB*B$;J>@7(9ZH0&=L+S!#O4A]A9]R4;PB@[U&@$Y6RU'WCU? M8%\MQIBF[E7=7&X'&#&/6':*@.6P1KQSC=2O0;=]?K2Z:WT-8"RJYW9<:\W, MT[ZO5/!1A,$D]/UD)^*$JGPVU2'<\S)]1Z0D1%<8]%$UO0Q/XVO+Q>K#O<[7 M)_%-X['I(K%R.Q$6:!/M=SLAB5 PR+J"$/HZ+"QE]I;V/4,W)(Y;U+7P9N_: M3=0M!%H1;?4"77NY]NF4@DXW7,"_*7TB#'PGT[X!QWXR!$<0UY8BC/$B=NY? M>"@JOOY/(U1-XO>YX?_"69+L5^R)K11[]LYX5H\\#W)FH6-/HFKY]+<2[MF6 MGSDLL; ^@7Y5>:F=9/]Y:7'J#SA,2E,ZLS07__JP5?1=1*B=XHS2KQL.8S# M7P65)F\)JTA1*MH8O ZHEVN/VO7U KELM_"L-J0(]MK M9(BK;/J+RNSKRZ+.TI1VHM,+X%@B>;E4J-M0Q'Z+>;9(]Y611I&Q2/]VL?&\ M&QT"^O0_4$L#!!0 ( )*#:$T6JX+SO0@ (UP 5 =G)M;"TR,#$X M,#DS,%]C86PN>&UL[5U;<^)&$WU/5?Z#0IZY7PPN.RF,O5NNP@L%NTG>4D)J M8&K%#)D9L/W]^J]'%JRTZ K>2 -YV%HL>EIS^ISIN4K<_/ZR??[KYI5S^ZVXR-&QF;59 I6%Q,"78QNS5 M& "7ZM(]$9;#Q(:#\612-]G6[98R?]H9/6,DY2;1T"/TZP[L9")2*V])2RO5U MM?K\_%QYF7&GPO@""]::U9UAZLZ;*_SJ5 M2(=B<<"H#11IPP^".<16--V9CD(_70)(43+4;;Y,'@-H4%PKXC@(LF*Q5569 M5#,YK?Y8"/MOQ6@^6@-W^7@W+%'>_T50 U,L/SCL^8=@\CGW(%FF8VT<%^<0 M 7@PE-OWE84_9/""V<<&>W^52'4[;*JUFE$V]G[Q\]ZUX?=M>,X-S[L+!<$X MS KXUT%^]RW_W MA?#A:G:NK1O>JW:YUV\U>K=/QU=RG MCSX/@C"YM?./'P\D$\QZGD55;%8KUUN9(,F[\G/.5H?A\V[&LE2<<1LX=HTE M8R.P/FRM[F4Z)>,9R&(IW6_6G#!.Y.MMJ9$/1ZH9JG\/_VS(UG14VYR D)Q8 M*&[U19_:P0L^RPA.3_)95 W$,7VHCO;_D6ZQ_HR_HI@CB/:;G >CB8@\ZEJ%IF[,&4XHY.L81ZX29:FZGK4:Y493 M&5>DJ-2&-\F,.+3(Q;Z\\HE1*S;[AMKJ1&%Z %KDT2$Q9\0ADH! /4XEL[XN MF8,5%TJ;\C6"QN1B>8!)7?U#PR"#[5ZM6\M9@FF9\8LS)2XM!O,#MEHQZB+Z MPW0V$$'E]V9!P)U>O=;,F6 M0=CM7KV==V]Z-+5IT6F1AG>K]&/S52W1I]NT"!J?$;49 &8;'.749-U%H]1Y M.<+ZC/C-@E"+->TAHPN5BNYA)A/70,.-@^!Q\M;=C25'EFVK+P/Q4WU MNW,Z/_CP3M0Y*#\!D:=X&FE/\7R[BS&:&[[[Y"#E3R ?*48'ADR(_M8DCDK! MGYEO-#,!5K][)NY=-YB=LIS@#NFST7N4XA,(^A;TE1[H(0(L;2446.@^J MC\"8K>_-B_ @GI@4'6)Y)M2F!)9M#I03GQ\Y5G_,V3QR+\!G43S^TG)QR&(2 M+"UZUPEL@6XBU_9W7Q>/MZ3HA^W2Q@JP!$W(T_\B8[6YF -\2"\04QX&1 MF^A1!@H.^EP@JB>3?P5?8*+V.'/+< MI? ]V9QJDZ)UW":%NHWQ=A_=GAL= S)FH^ XF +NX>U__-O9V&[VLI8F7< $ MX3[,YV!%K5?\VY7(:8M$51SG6UN"ZKE[_8*Z>*3[5-^W,%/'G?I+[R#8 GN] M>B_OM)2/RK[;FSDE>EH,@T_;A>LV>HVKO)_1/I&F+'MR.[Q:4/O1)%0A&-$I M-HK1//#\V_[AMZCQ;ZK"%R"&$P*AQ]+'/:PY6,0-+'YVP.4+IP,KA@.V_[G7 M(T22IN@%2.3H,&@QCYHN30[NJ[=P0J#FA'&*"#>^ UD *[%F;K#H=/AJRPB M#WW,,<.(?P5U^DEDP:9QB.&<7*:NC ^/)ZDJSWFS J.2F)?\DQU0ENSC*W.1XDC"[TFA5^PN*B)0"IPX954VQ$$P M2DV,TG^KLB=&3XL]:^R%W;V>SZQO8?@X1+Z[*D)BZ1T43V(G$GRHF!.#D;C8 M6^2L](%0DUHG9*40!\633&&S4MKH:;$2B. L %M\P-B[QP)&;C7%PPMPBPB( M.N":6*YX@CJ1SI <=%0,M-AG\D,;$@KJ& 0'._))@TC["Y-!,G8MQBH36'O] MZVB>AOY(^PN@/QOVQ$ZA$ ,/OZ0?A=BH7T10VZ38O4K $98%<>/45(4O0!DG M!$*+_22_\M4+"G! YKUW;ZA&6Z.90Q;!Q_MCTD:\@V"06KU&MZ!+*^^31XX( MAAX[3/XF\:?)N3IOX8V6HD025^0"9)$9?N*>4-%T\"TU^DXG9^I;?.4N3!'I M8Z#%GDY4C^EMC+KH,"^^70#U&U"9M9+D[&(%=%1@CMSH"3O.?[/_@;O?_@]0 M2P,$% @ DH-H30F"AEAJ%P !F ! !4 !VCL6\9W I?[X^T[$=VWN4+KSM[_^^[]]^X_=W;^?W5];;N!$4^*'EL.( M'1+7>GJS!H2%XM,YY8X7\(@1Z\;V[3&1!3]_.CC\U/NT;^WN)@V=V1PJ!KXE M6SSXM+_X99 T&OA?K?W]O9.]@][^B77X]>#XZ_&1=7>S*'@#1(YH;DF/^K^> MH#<+&/7Y]YU)&,Z^[NV]O+Q\>GUBWJ> C:%B[W!O7G G+OGUE=-,Z9?#>=G] MO;_?7#\X$S*U=ZG/0]MWEK5$,ZIZ^Z>GIWORUT51Z-X-%V73U!SOQ3]"44Z_ M#8H40IEP5+6T+\:W=>;%=\VMT_V#W<__3*W1T0EV5]8X%'[LG(DK1^ M#=]FY/L.I].9)WB4WR:,C+)DCVS^)#L!C1G;]DQ"L4>\D(LOHD6^*S[M]O:3 MSOZ3$'>Z8XF??MY?+5I;:T@4V!-E]RY>0<,X??+(A0_ZQZ0PKBD/^8ZU5X[T M9S;U)#V]T\.>I.8A!*43NCH(?!>Z(2[\P0./ND(9%[_RX6@X2[KFZ]0+><-8 MFE+/@P*?G& :TU^M]4Z8NK,9?)J0D#JVURR'*UUMS.YR[AFRL>W3?\IN8*:A MT.T=(QQZDY_ZOOM QS[,'H[MAWW'"2(_A D/OM^36<#$WW= NT,)O[69(/>9 MG)/0IEX)T%LB!Z?8'J+IU&9OP]'5=&8[X7#4=X.9;(0[GWN?A_XE]6':I+;' M<0BV"L$UBGX03*1[X@/MM<',Z96 MIC>GHD8AW1-/S.LP@X=OC\P& F2'F^AJ;I,)^39S2EHHJU;0W+@2YL^Q9,SV M8/U)&DY3O:A%_7#/I=.]I,R>K- @0="7L'4"?]_40\N<=7%MK;G%#.PA21\*]5 N'3GW+")$S(X>?)U*L3NZIL0[)?7P_4@L_3G171JSC89OG_^?GP\YG1VU ,C01.";Y+%7SF!KI1I"HNL&9*+@U[+!!@: MVA%(/*'9*/&5,JU*_&!#B:_0/F,T8+#+DU!B$/]\.0/;BUS!GZMKLJE@0T#( M35?!57B-[(SL5];J%7G']OA7)_!#L ,O/%D4("9C\LRE MTB#=DV?B1X3WGWC(8+NL@6B]6)*R/$FB!B8P(;//>$$ M)#&!X7L."Z47S 1W"=U:&\!8!\-TEJMV60O!R \VR!Z(Y\6GOCT-IWIR!=P94XYS7#E5L+@VE7"K-V,P'MK@@-0E;(^YC($*[J$-GDN<' MXD3 "5FYNMX1]C"Q&9%D"B\!]80V:Y#-K=4NDG5X2')9PH;< M'X2.)T!9_QFX')/;2,AD.)+$#Z-0W'$25\** 5JUL79QKL.Y4I73?/B_[67C M'[N(B5RYH)/&P1 @>;Q9@*3U6Z;;O_PK!4Q6V%.*Y6+I9$]N""AB* O5V(9P MRD*,+,?7 8KI54.L,NRO8)V.PR]+:& !U.9,O7OX,=!040[#H5TA[5P//\CP@0 %XW&B$9="-3&L,'Y+Q7#;1+^ MU@1T+UR\1\H*W!L6BE3&LA\4P+LI1^]Z4EG)[%/"X'/7V>_O6;CKQTJZ5 M)NJ_+4F6<+*D";. BM%FK6D3?ZTH,Z:DV?]MB#P+]9O"8TEW3/K.07$ES]+ M"&Y.C9P:53LHWNG3RU8)Z9 M*,I) ,':_ @=+'/,&"TK=5$D[I]*^IN&3LW=]B.4]7\7L0QS$V<_G/F3B#@/)'O5,CL@7K8G &F?0U,U<68PD!<,(V'(X&C+@T MO+0=ZHDL2/IE4%^\@Q7OH.$53\\L4N"NA?'*C([S_&I(%KT\Q^.:$M$"Z^JKX;MP]=T+_XF_C/ $;J-I)%,@G@/&CO;2;9&* M7;KXFE2<,C+ %F$'&RN'$)=?@I3^$(XT<9P']B/5WY8R5^GR4*P-D,W<8X;W MBO-(Y(0?,G'4/AS%"5P+@*RKV.6I6=M0ZV2P%8##[S(9L,+'],;GRTP6H[]"91P;Q*B6.CD %6!W8,_A% MNU:5:Z++>X]M:%$Y:6!3A_34*SCAZJ42G?/I%J8[I\MFFC']G]2UU'JP?#C]< &CN: M1?D:0!6;_"/-?,L7_,J.:./=VFJ-=1^?4O\\MZE,ME(WD#6,+]W4O9,I CW"^*-M2OFLR;#0#&1;D1L:>P9;32:%9A!#GNKV M/22YU"1=;P;/K4N&&8?PY#R\LUH(0U;V9O!;Y10=7/')(;\G#J'/PL:"&600 M,::/OS17P; M5NN@XB*GA@=L(*6S%\?1+ M,?"A30J37P=+L-ZV7'!771C0-#MIBW;7YXM*.=H$Q%$:QWN2JV&*E,7!27]Y:C<@? M631]BCP/YEP?ML+4B<)\T1>HA.&VV&7\JCEPN/#JFL$18F9:'VEQ=;@,1N#/SJ(B>O8-/WIJ)6;IVY]DE:AA29@ZQ#:-M30VB M2@U1=5!]Y/Q E/-#F0ZBSDW?-F7SN+/?YIG[[PT9YE9+M0M8'6X:+2O-IP:> MQPQ+[QX?AA,P?!PGFL&T_28>451G_"U0JUT4ZO"5%&8-VSB1I%Z\SFC\L+38 M+^J2ZJF+MHM5G3X/-3\H 1+A55?3&0,#2?+Y@^DCX$T5V@6K3O>&B2M\D'%. M2'8V$!L.6$^!7T,T9Y&*[4)8AP>D#'>-+UHQ$:)OD0%J>2+%5R9OL8;VGY+W M]^)@5=5JME%S[4)9FQ]D(YZQC54%S@^>!/[_CN;*@>>MFB[TJ_-$Z+E!]N 2>\S))U4GYE?6;1=@&KU=BCYP090 MHCWF9W!7"[5[.%VGHV*5DRXO#ZQ?A:CX6NW1^N6!=-O_9<6MU_'8;$T7EYP) M<2/Q$H'Z%>*TF7#VMBR3#*G^B\U<4R;'&MOOYEY78@8-/)MS8$* :0@3-I3O M_A9#8Y@K7RY?EP"".39-E#%:554021!QKDYF<@8I^-AN'#*AM(<'IY\Q/;NW M(39*WC# !6M\X$MZ^^9T78J"&$*)]?J6 41!/0+I/\ 6G/"S.VB2,$9G>4+9(]W>%6K$!LDS7%X!?+VK&=6>U$)*U M7Z5Q*LG/R7X'LL^NB8>G)P>(,H&6PT/)2N/W4^2L.91M"G(>7V#\OCT27W\Y M):\&AA5=K4D+MUP>"]@&QJ/P( Q'5[Y+GZD;V9YA3=&4[6!QT:0Z:W1QT7"/ M'M _:#BY)YX4 )_0V6-PX8!/P\)/Z>,.%"/ZU=.4VD,JV9%;5TLJR;^FK_=29C(020> MQP(UM&'QT .A+XMA^[LI#'KNV@)A.!I1AS!QY+.X,9&+AJD2AA2M-<%B8K-Q M?,X",)Z&HP)SE:XDAM2KFR*AXPW;F6]LZII3SZR4Z<#,UX#4J)F_PC4"K*HS MN>3%=PMY0)KI"LG>0*GS&;=O(]Q_:-"F764-\,^G)\'8=G6B54B((%.V> M\)!1)RQR5J0IBV&WTN1XR>8V58H 9!S^S'ESC2":2B/8=_3%J &,2 ]7?" MY3/&>I,O4Z(#@T^30+]1@R_#,QZ4C*OL2ADD!I9"OQ2"1F07E19U=MW]2O7,)[_R?A1.@-A_)H^2KL1=@!EX\0I,4D[N8(=%[H5]:(J?;Z*G#@QH MS0M&S4;>-R&[[=:^=:XJ.,TV[ G)IJ#!,5R3$NI%^*&$F_64V64<'9Q^Z?7P M;)>V5S&58FW".LH0<*&WBM3E,&RN&AP^"YM*S7WCIFNFV\N"X%QBVH>U#L[E M=AFZ*:M,9Y1=YSPT7D?#[:>?KU\LF1FY/F/8% 6X-8GMX]MG(SJ1;&2&)H/9XPO(B9T#=D]'4_".97S14N9R*9H30S.J :0+,I^MPC^ M]$EE##-UNTQ?WQ6*&0%@,]52B\&=S88L?N[B=]N+R/PE]OR54U^SRTSWK:VB M>O:QH9U>[^46(@=C0_DN$^$W;%#KF6X^ YSH+['D^6-P1F(RY*9Q/I^H9N!B M];I,DM_@[%N,^<:QD_V]0!;.$6BW,% MEL%\I6*GZ?@[P'N%?6Q8PY1$1:#Y4P0&]X7-Q(L<_#K@O._)7HG[&(!)'E*' MSF0VWP?BB,?@1 XDFU-'HPF;-]OI4P#-ZLGFPL&F16@#K_Y8M^O- MK=;I&P,-[WESF=\*E#.':(L?>?(KU[W_4;&M3A\LZ$ ?\B72N'%_:5,F/3'+ M[I6'0'F%.WV@H$&CWL RN@&\=+-)BO.=D4FQ3E\A:,WUF#"+#;5LJLD"Q["F M"IV^:-"T^:UG&S>F)0\+BE;N]'&$-K'>GC,#Y2(_?^9W:>8/;,\C[MG;A>U, MLF7+F%/EVNWTU88.3*MRTFG?OPXENE1OT9Z:E>G6O7K-2*O=Z-^BWDTCLU]MJDG B O R;YKEL'<[MK M5Q%;=1PV)[1WHXVQGWWY#'S\<.[CQ/:5@[%N[2S=?;O:VJJ#LSTAHM->L2F) MMY[G8%O*.[5 J-R;K.3UD0P;%^MJ;;6K5ZTZ2BM*!)V25)[,@V0M1%6YVVJW:MQB@V+;IWHY\+AW@?QN@TGK$SYQAUZV:!#MO5R_8C+!L2 M&TJ=?,KG]4F9JBU)BA9-HZ3K*QNIQ M^9"LM$.'HQ%A\X_*\.%-FFM7/=H+4MU(*-BFH4'@/Q,F$@HDS\7%^^KX,]B> MVJ"'_'KMWK%KUPN?SSVN]Y:3<*PEP6LB21Z*/GN[C'PG)K3/B%WV?>:#8N\S M+^FQ@E%<9E>29*5ILA*BK*A"\Z[S(A^($8U]< M^8\W>W)B*/;&HKY.!KIA4C/6P/AJ;<-SG%$>6P*W<0;,J8-D M0BR@R 50P_ITH%!!L'9M3_-TEJ$\G$/Y4NM73GEG/ MK.V-TFM6>^HNG5KCV8V)"P?%0DFT66299*E;_O2'!$@66<23KX3LC=A9JZLR M$[]$90()(('\W;]_V<;DF69YE":__^K=F].O"$W"=!TEC[__:I^?!'D815_] M^Q_^]__ZW3^=G/S7V=T-6:?A?DN3@H09#0JZ)@\OY)QF!7QT$>5AG.;[C)(/ M01(\4D[XW9MOWK\Y??..G)R4@LZ"G#&F">$2OWGSKO[FO!2:)C^0=^_>_O;M M-Z?O?DO>__#-MS]\^QMR^Z$F_,! ;B(C91PE?WE@K1&F:)+__JNGHMC]\/;M MY\^?WWQYR.(W:?;(&$_?OZT(OQ*4/WS)HQ;UY_<5[;NW__7AYE/X1+?!293D M19"$!RX0(^-[]_WWW[_EWS+2//HAY_PW:1@4O.N-N(B2 OYU4I&=P$?_NS9=\_17K T)^EZ4QO:,;P@'\4+SLZ.^_RJ/M+@;@_+.GC&[D*.(L>PO\ M;Q/Z"#\-M/ ]M/#N.VCAG\N/;X('&G]%@/*GNVNE0M^W9)5,;T=%6701%J[H MBC:R&/YUPQ"TL-$OS.C7=%VA U[-+\E%KI--FFVY.2T?\B(+PJ(2Q.$+299\;VN( MP+K,VCB#+*Q$LS\-:I<4;\.4^6-SFN:JT?"%TE&Q&Z;(+\@2O$9J_'(-CQ:>$MC8N\^H0[T\GINW*( M_.?RXS]]8C\FG[#N@X?#D%-V@(IH7D?10P6OD%-,X@(R.]$UWS&*FHC\PLFF M,>>"13?T9G*L"';*)B1ZS?[,38HU")'MM0-9:K,U%9[='D'0V0.0$DZ+;<#C M@+:UY+PRY9R&;Q[3Y[=K&@DK9G\<&R_[J)X_[IG<(U6Z7\]KJ"IX8)['W\UF ME/*&U7,KT,QK@6,@G,S/$N!'W\]O<%* E<6UOIS5Y"0M=W[1 MFH8 T?Q&-QSCY*/<+ %M$*".A!(%ZP!'$ M;,6Q)D".-SJ.B7IRT[V*\C"(_YL&V17[Y#B\U%+BF:\"]+$!'Y&AF+ 4@]H< M!#D!>L(9\,QX;.0SF;)P*#MC;M%BF[,$N-R@&X2()MU!832-CVG)IW?@$VP*QM6TI\% MD(GTZ67[D,KT./I^?N.4 JS,LO7EK 8I:;GSRY8T1!#-//9\V@9Q?+;/HX3F MLA6YE IK[)&";8\]+1*$L4?2OLJ5.2FI:&?^W2^W-'MD5O=CEGXNGL[3[2Y( MU'./@AK+#K3@V_8@)46P"PT.E7U4+$3PD))I[L5BNMVFR:DVA94);1EJH7.BY5A=F@Q[5,!O&NF1X1(UBI%H; )4FV'39S1;FG'=M K MS 'G^0'/KL^#_ G^N_SK/GH.8H8IOZ,,>A2RJ0&^6";K]@<-2D5'#)2)XR>C M=$33GP8)G-WO1D#;-7)&Q>]J\#\:]&19L,^R[ 66B'\,XOTT>^Z[*EU*Y[63 M*1+"'_1 OR"4?9INB( VH=8L3,P*C_1^H(]1DL#O/:WVQE%Z5KT1XY4P M3/=TCG0+\@">UT_WSN?)O171"M+[_L8 '/AJA5\42S5L2I M4-^*$\>Y'91J^K@%V^RN;HVI8VLE)RE9>;S$F4E[>8/C^L/UHH(UY_-CRA4+ M6XL?/*>Z3IX9C#1[80."0O\V"8Z;R& V_:'Y_>R&WVV\8PDUR0*F,AP[=H 9 M45^VF6SV&;S85C)N)^%N(UEM'TUCEVD1Q-9[1JHD"Q#BS:!YFZ5L^5:\W#*, M_!$'MMK9P7F$>A#5LV#%'F8UVD&'FAXAVC"!D4S'@H5P'O&"1L6%-RP/403B M"5K1(X?GC:CH([,][?"MH,5Q RWPIOU+"6=3D.);NCAQ[ MH!=@M?,6;O"ACCJ0P@U]G,&G<8%O;310\1'%4L.B;S0,\-^8IC=?, MK6!.*%X,1Z[V[#@6ZZI>TZ9M>6>W>C=@'<-KL/-XI"F " GH9[HCJA@^)Q=8H.. =VO+%(($M M?KO3L6-BW',Q.739B5B;$NTL3 9#??Y24OMQ_.4&?2>H4:T[V]-UUT?5:JKH MT6Q>_F&;"(KGF7G.(VV=-'J1+ M1X.4X#>+FCSDZX]I0%X0N_?F;S;*;Q'Y^[.Q]#M8V?*63HA[3R> M, WV>:>#\MD7?G%5X_!M,KR!7P;W>+1OTJ ,\5T TB&Q?@AHNEO#5H.Y/=Q< M//.S"S+R#-3D5Z=O3D_?P1U8DL/;/POR[MO3Q>DI_T]\Q(;\??&49M'?Z)H$ M!?G$?F6Z?6 <[T\7A)'7!I9$"9G1\,B>J;Q-.].6FSH]_@11/\C'LBN MU_R5GB"^#:+U=7(>["(6YJI.X5342(>Q>O"MHU@YZ?P'L3HT"**$KB^##"[^Y\LPW&_W,;PY=4$W41BI M0D4;1APOL%>IZ1!FKME]PQ92Q] J1E)QD@8K*7EQ/*:W3DT-UG(-,!=6UI&T M/PLINP64!PLGBT6'(DUWGJTR:\1BQRR7+):\V,J5)D^;MP<5;.B;OEIU7'+W MO69OSI6$6_ MV#*CO?SAH-K1XQ\6G!CO?UC#DCV5(9C+O0W&3E89$0+$3@<4"1-/!:.] S*& M?L>;(;XXEWB$>5EONECU0I?)!V=2J:)VHF,.9.>1PS$Z3?F.]H'/!T=QUJ5T MD,XNH%^.4/76PK^E5$<5[3I*2>V)(ZA74 I2? ?0KCMDQH^Y<.J%WJ\E MDT,!/CL63TS?L%+RHO2>/1@K3T!?(/77P\.ET742IEM:EW(SI$XKJ;'>H]:" M;S]-+25%>*5:@\.V3E[-SKQA0U8[F@60&V MTZ;:- A)4C( DI0H08;^')<;7L0D^@JH00]LX]09)9HQ&HP0:Z?"#AYF*)H7 MJ\V/:;KF>2(T>XY"FG]*X[5AQ+1AQ I+;55J!Z)@NZ89DZ*.S6@5GG?US#3>7\,@5K%R I^:53-P??',".^/'L_T?LS3/ M;[-TH[RW7X[;7=^:DY!! E.RJ@MQATG(5_'[!^(-ZW+ MA6;R6!;A,BWQ-/1(;\&9%&B]!JZP6;%N*4%WHI-5&N0K0\6,M)"T7::TP- \+"TXA&LMP3/#P@:7!5 MKH&U/S) $[@?L#YP(5X0HS&3^A
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
'-D4$L! A0#% @ DH-H31:K@O.]" C7 !4 M ( !I9P '9R;6PM,C Q.# Y,S!?8V%L+GAM;%!+ 0(4 Q0 ( )*#:$T) M@H98:A< 9@ 0 5 " 96E !V&UL4$L! A0#% @ DH-H3:.S M SA;)P S)4" !4 ( !Z_0 '9R;6PM,C Q.# Y,S!?<')E :+GAM;%!+!08 !@ & (H! !Y' $ ! end